{"data_date":"2026-11-08","library_size":29380,"matched_against":"each record's title and abstract (summary field), case-insensitive","n":286,"page":"https://alzhub.org/answers/lecanemab","query":"title or abstract mentions \"lecanemab\", \"Leqembi\" or \"BAN2401\"","studies":[{"alzhub_score":15,"alzhub_url":"https://alzhub.org/study/fda-approves-leqembi-lecanemab-irmb-under-the-accelerated-approval-149a0541","doi":null,"journal":"U.S. Food and Drug Administration (announced via Biogen press release)","n_participants":null,"pmid":null,"source_url":"https://investors.biogen.com/news-releases/news-release-details/fda-approves-leqembitm-lecanemab-irmb-under-accelerated-approval","study_design":"regulatory decision","title":"FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer's Disease","title_match":true,"year":2023},{"alzhub_score":14,"alzhub_url":"https://alzhub.org/study/fda-converts-novel-alzheimer-s-disease-treatment-to-traditional-826d45e8","doi":null,"journal":"U.S. Food and Drug Administration","n_participants":null,"pmid":null,"source_url":"https://www.fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval","study_design":"regulatory decision","title":"FDA Converts Novel Alzheimer's Disease Treatment to Traditional Approval","title_match":false,"year":2023},{"alzhub_score":11,"alzhub_url":"https://alzhub.org/study/biogen-to-realign-resources-for-alzheimer-s-disease-franchise-aduhelm-49a9a379","doi":null,"journal":"Biogen Inc. press release","n_participants":null,"pmid":null,"source_url":"https://investors.biogen.com/news-releases/news-release-details/biogen-realign-resources-alzheimers-disease-franchise","study_design":"company announcement","title":"Biogen to Realign Resources for Alzheimer's Disease Franchise (Aduhelm discontinuation)","title_match":false,"year":2024},{"alzhub_score":74,"alzhub_url":"https://alzhub.org/study/lecanemab-in-early-alzheimer-s-disease-22dd8fce","doi":null,"journal":"New England Journal of Medicine","n_participants":1795,"pmid":null,"source_url":"https://pubmed.ncbi.nlm.nih.gov/36449413/","study_design":"phase-3-trial","title":"Lecanemab in Early Alzheimer's Disease","title_match":true,"year":2023},{"alzhub_score":15,"alzhub_url":"https://alzhub.org/study/leqembi-recommended-for-treatment-of-early-alzheimer-s-disease-chmp-6280b4fa","doi":null,"journal":"European Medicines Agency","n_participants":null,"pmid":null,"source_url":"https://www.ema.europa.eu/en/news/leqembi-recommended-treatment-early-alzheimers-disease","study_design":"regulatory decision","title":"Leqembi Recommended for Treatment of Early Alzheimer's Disease (CHMP re-examination, reversing July 2024 refusal)","title_match":true,"year":2024},{"alzhub_score":10,"alzhub_url":"https://alzhub.org/study/national-coverage-determination-monoclonal-antibodies-directed-ff44148a","doi":null,"journal":"Centers for Medicare & Medicaid Services","n_participants":null,"pmid":null,"source_url":"https://www.cms.gov/medicare/coverage/coverage-evidence-development/monoclonal-antibodies-directed-against-amyloid-treatment-alzheimers-disease-ad","study_design":"coverage determination","title":"National Coverage Determination: Monoclonal Antibodies Directed Against Amyloid for the Treatment of Alzheimer's Disease (NCD 200.3)","title_match":false,"year":2022},{"alzhub_score":69,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-aria-in-anti-amyloid-therapies-912127c4","doi":null,"journal":"Alzheimer's & Dementia","n_participants":null,"pmid":null,"source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13099593/","study_design":"systematic-review","title":"Amyloid-Related Imaging Abnormalities (ARIA) in Anti-Amyloid Therapies for Alzheimer's Disease: An Update from the Alzheimer's Association ARIA Workgroup","title_match":false,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/lecanemab-for-alzheimer-s-disease-effectiveness-and-value-final-40d8b15f","doi":null,"journal":"ICER (independent health technology assessment report)","n_participants":null,"pmid":null,"source_url":"https://icer.org/news-insights/press-releases/icer-publishes-final-evidence-report-on-lecanemab-for-alzheimers-disease/","study_design":"modelling","title":"Lecanemab for Alzheimer's Disease: Effectiveness and Value \u2014 Final Evidence Report","title_match":true,"year":2023},{"alzhub_score":63,"alzhub_url":"https://alzhub.org/study/long-term-safety-and-efficacy-of-lecanemab-in-early-alzheimer-s-41355080","doi":"10.1002/alz.70905","journal":"Alzheimer's & Dementia","n_participants":null,"pmid":"41355080","source_url":"https://pubmed.ncbi.nlm.nih.gov/41355080/","study_design":"phase-3-trial","title":"Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the Clarity AD open-label extension study","title_match":true,"year":2025},{"alzhub_score":71,"alzhub_url":"https://alzhub.org/study/lecanemab-treatment-in-a-specialty-memory-clinic-40354064","doi":"10.1001/jamaneurol.2025.1232","journal":"JAMA Neurology","n_participants":234,"pmid":"40354064","source_url":"https://pubmed.ncbi.nlm.nih.gov/40354064/","study_design":"cohort","title":"Lecanemab Treatment in a Specialty Memory Clinic","title_match":true,"year":2025},{"alzhub_score":61,"alzhub_url":"https://alzhub.org/study/cost-effectiveness-of-lecanemab-for-individuals-with-early-stage-38484190","doi":"10.1212/WNL.0000000000209218","journal":"Neurology","n_participants":null,"pmid":"38484190","source_url":"https://pubmed.ncbi.nlm.nih.gov/38484190/","study_design":"modelling","title":"Cost-Effectiveness of Lecanemab for Individuals With Early-Stage Alzheimer Disease","title_match":true,"year":2024},{"alzhub_score":53,"alzhub_url":"https://alzhub.org/study/clonal-expansion-of-cytotoxic-cd8-t-cells-in-lecanemab-associated-aria-41617706","doi":"10.1038/s41467-026-68921-3","journal":"Nature Communications","n_participants":3,"pmid":"41617706","source_url":"https://pubmed.ncbi.nlm.nih.gov/41617706/","study_design":"case-control","title":"Clonal expansion of cytotoxic CD8\u207a T cells in lecanemab-associated ARIA","title_match":true,"year":2026},{"alzhub_score":74,"alzhub_url":"https://alzhub.org/study/clinically-important-benefits-and-harms-of-monoclonal-antibodies-38253509","doi":"10.1370/afm.3050","journal":"Annals of Family Medicine","n_participants":23202,"pmid":"38253509","source_url":"https://pubmed.ncbi.nlm.nih.gov/38253509/","study_design":"meta-analysis","title":"Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/value-based-prices-of-emerging-disease-modifying-therapies-for-42125995","doi":"10.1002/alz.71308","journal":"Alzheimer's & Dementia","n_participants":null,"pmid":"42125995","source_url":"https://pubmed.ncbi.nlm.nih.gov/42125995/","study_design":"modelling","title":"Value-based prices of emerging disease-modifying therapies for Alzheimer's disease in 174 countries: a cost-effectiveness and threshold analysis","title_match":false,"year":2026},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/the-cost-effective-price-of-lecanemab-for-patients-with-early-40730714","doi":"10.1007/s40273-025-01527-7","journal":"PharmacoEconomics","n_participants":null,"pmid":"40730714","source_url":"https://pubmed.ncbi.nlm.nih.gov/40730714/","study_design":"modelling","title":"The Cost-Effective Price of Lecanemab for Patients with Early Alzheimer's Disease in Sweden","title_match":true,"year":2025},{"alzhub_score":49,"alzhub_url":"https://alzhub.org/study/cost-effectiveness-of-traditional-and-novel-neurotherapeutic-agents-41837605","doi":"10.1177/13872877261430376","journal":"Journal of Alzheimer's Disease","n_participants":null,"pmid":"41837605","source_url":"https://pubmed.ncbi.nlm.nih.gov/41837605/","study_design":"systematic-review","title":"Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review","title_match":false,"year":2026},{"alzhub_score":37,"alzhub_url":"https://alzhub.org/study/the-social-value-of-lecanemab-for-patients-with-early-alzheimer-s-42108615","doi":"10.1177/13872877261447312","journal":"Journal of Alzheimer's Disease","n_participants":null,"pmid":"42108615","source_url":"https://pubmed.ncbi.nlm.nih.gov/42108615/","study_design":"modelling","title":"The social value of lecanemab for patients with early Alzheimer's disease in Japan","title_match":true,"year":2026},{"alzhub_score":65,"alzhub_url":"https://alzhub.org/study/microglial-mechanisms-drive-amyloid-clearance-in-immunized-patients-40050704","doi":"10.1038/s41591-025-03574-1","journal":"Nature Medicine","n_participants":null,"pmid":"40050704","source_url":"https://pubmed.ncbi.nlm.nih.gov/40050704/","study_design":"case-control","title":"Microglial mechanisms drive amyloid-\u03b2 clearance in immunized patients with Alzheimer's disease","title_match":false,"year":2025},{"alzhub_score":54,"alzhub_url":"https://alzhub.org/study/the-alzheimer-s-therapeutic-lecanemab-attenuates-a-pathology-by-41286448","doi":"10.1038/s41593-025-02125-8","journal":"Nature Neuroscience","n_participants":null,"pmid":"41286448","source_url":"https://pubmed.ncbi.nlm.nih.gov/41286448/","study_design":null,"title":"The Alzheimer's therapeutic Lecanemab attenuates A\u03b2 pathology by inducing an amyloid-clearing program in microglia","title_match":true,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/fdg-pet-and-mri-for-monitoring-immunotherapy-in-alzheimer-disease-37314733","doi":"10.1097/rlu.0000000000004710","journal":"Clinical nuclear medicine","n_participants":null,"pmid":"37314733","source_url":"https://pubmed.ncbi.nlm.nih.gov/37314733/","study_design":null,"title":"FDG PET (and MRI) for Monitoring Immunotherapy in Alzheimer Disease","title_match":false,"year":2023},{"alzhub_score":42,"alzhub_url":"https://alzhub.org/study/advanced-brain-imaging-for-the-diagnosis-of-alzheimer-disease-37639461","doi":"10.1097/wco.0000000000001198","journal":"Current opinion in neurology","n_participants":null,"pmid":"37639461","source_url":"https://pubmed.ncbi.nlm.nih.gov/37639461/","study_design":null,"title":"Advanced brain imaging for the diagnosis of Alzheimer disease","title_match":false,"year":2023},{"alzhub_score":78,"alzhub_url":"https://alzhub.org/study/updated-safety-results-from-phase-3-lecanemab-study-in-early-38730496","doi":"10.1186/s13195-024-01441-8","journal":"Alzheimer's research & therapy","n_participants":1795,"pmid":"38730496","source_url":"https://pubmed.ncbi.nlm.nih.gov/38730496/","study_design":"open-label trial","title":"Updated safety results from phase 3 lecanemab study in early Alzheimer's disease","title_match":true,"year":2024},{"alzhub_score":60,"alzhub_url":"https://alzhub.org/study/tracking-neuroinflammatory-biomarkers-in-alzheimer-s-disease-a-39080712","doi":"10.1186/s12974-024-03163-y","journal":"Journal of neuroinflammation","n_participants":null,"pmid":"39080712","source_url":"https://pubmed.ncbi.nlm.nih.gov/39080712/","study_design":"longitudinal study","title":"Tracking neuroinflammatory biomarkers in Alzheimer's disease: a strategy for individualized therapeutic approaches?","title_match":false,"year":2024},{"alzhub_score":63,"alzhub_url":"https://alzhub.org/study/eligibility-rates-among-racially-and-ethnically-diverse-us-37830926","doi":"10.1002/ana.26819","journal":"Annals of neurology","n_participants":156,"pmid":"37830926","source_url":"https://pubmed.ncbi.nlm.nih.gov/37830926/","study_design":null,"title":"Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease","title_match":true,"year":2024},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/lecanemab-reduces-brain-amyloid-and-delays-cognitive-worsening-36948153","doi":"10.1016/j.xcrm.2023.100982","journal":"Cell reports. Medicine","n_participants":null,"pmid":"36948153","source_url":"https://pubmed.ncbi.nlm.nih.gov/36948153/","study_design":null,"title":"Lecanemab reduces brain amyloid-\u03b2 and delays cognitive worsening","title_match":true,"year":2023},{"alzhub_score":67,"alzhub_url":"https://alzhub.org/study/lecanemab-for-patients-with-early-alzheimer-disease-bayesian-analysis-37040116","doi":"10.1001/jamanetworkopen.2023.7230","journal":"JAMA network open","n_participants":854,"pmid":"37040116","source_url":"https://pubmed.ncbi.nlm.nih.gov/37040116/","study_design":"clinical trial","title":"Lecanemab for Patients With Early Alzheimer Disease: Bayesian Analysis of a Phase 2b Dose-Finding Randomized Clinical Trial","title_match":true,"year":2023},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/lecanemab-a-humanized-monoclonal-antibody-for-the-treatment-of-early-38095619","doi":"10.1177/10600280231218253","journal":"The Annals of pharmacotherapy","n_participants":null,"pmid":"38095619","source_url":"https://pubmed.ncbi.nlm.nih.gov/38095619/","study_design":null,"title":"Lecanemab: A Humanized Monoclonal Antibody for the Treatment of Early Alzheimer Disease","title_match":true,"year":2024},{"alzhub_score":57,"alzhub_url":"https://alzhub.org/study/lecanemab-questions-38484213","doi":"10.1212/wnl.0000000000209320","journal":"Neurology","n_participants":null,"pmid":"38484213","source_url":"https://pubmed.ncbi.nlm.nih.gov/38484213/","study_design":"randomized controlled trial","title":"Lecanemab Questions","title_match":true,"year":2024},{"alzhub_score":52,"alzhub_url":"https://alzhub.org/study/comparison-of-the-efficacy-of-updated-drugs-for-the-treatment-on-the-39550061","doi":"10.1016/j.neuroscience.2024.11.029","journal":"Neuroscience","n_participants":null,"pmid":"39550061","source_url":"https://pubmed.ncbi.nlm.nih.gov/39550061/","study_design":"meta-analysis","title":"Comparison of the efficacy of updated drugs for the treatment on the improvement of cognitive function in patients with Alzheimer 's disease: A systematic review and network meta- analysis","title_match":false,"year":2025},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-with-anti-amyloid-antibodies-35401412","doi":"10.3389/fneur.2022.862369","journal":"Frontiers in neurology","n_participants":null,"pmid":"35401412","source_url":"https://pubmed.ncbi.nlm.nih.gov/35401412/","study_design":null,"title":"Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease","title_match":false,"year":2022},{"alzhub_score":80,"alzhub_url":"https://alzhub.org/study/lecanemab-in-early-alzheimer-s-disease-36449413","doi":"10.1056/nejmoa2212948","journal":"The New England journal of medicine","n_participants":1795,"pmid":"36449413","source_url":"https://pubmed.ncbi.nlm.nih.gov/36449413/","study_design":"clinical trial","title":"Lecanemab in Early Alzheimer's Disease","title_match":true,"year":2023},{"alzhub_score":81,"alzhub_url":"https://alzhub.org/study/a-randomized-double-blind-phase-2b-proof-of-concept-clinical-trial-in-33865446","doi":"10.1186/s13195-021-00813-8","journal":"Alzheimer's research & therapy","n_participants":18,"pmid":"33865446","source_url":"https://pubmed.ncbi.nlm.nih.gov/33865446/","study_design":"clinical trial","title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-A\u03b2 protofibril antibody","title_match":true,"year":2021},{"alzhub_score":53,"alzhub_url":"https://alzhub.org/study/lecanemab-and-vascular-amyloid-deposition-in-brains-of-people-with-39158850","doi":"10.1001/jamaneurol.2024.2579","journal":"JAMA neurology","n_participants":15,"pmid":"39158850","source_url":"https://pubmed.ncbi.nlm.nih.gov/39158850/","study_design":null,"title":"Lecanemab and Vascular-Amyloid Deposition in Brains of People With Down Syndrome","title_match":true,"year":2024},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/lecanemab-in-symptomatic-psen1-p-met233val-early-onset-alzheimer-s-42676462","doi":"10.1002/dad2.70468","journal":"Alzheimer's & dementia (Amsterdam, Netherlands)","n_participants":null,"pmid":"42676462","source_url":"https://pubmed.ncbi.nlm.nih.gov/42676462/","study_design":"longitudinal study","title":"Lecanemab in symptomatic PSEN1 p.Met233Val early-onset Alzheimer's disease: Neuroimaging safety, regional amyloid-PET dynamics, and longitudinal plasma biomarkers","title_match":true,"year":2026},{"alzhub_score":60,"alzhub_url":"https://alzhub.org/study/eligibility-for-anti-amyloid-treatment-in-a-population-based-study-of-37586881","doi":"10.1212/wnl.0000000000207770","journal":"Neurology","n_participants":null,"pmid":"37586881","source_url":"https://pubmed.ncbi.nlm.nih.gov/37586881/","study_design":"cross-sectional","title":"Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging","title_match":false,"year":2023},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/lecanemab-ban2401-an-anti-beta-amyloid-monoclonal-antibody-for-the-36749830","doi":"10.1080/13543784.2023.2178414","journal":"Expert opinion on investigational drugs","n_participants":null,"pmid":"36749830","source_url":"https://pubmed.ncbi.nlm.nih.gov/36749830/","study_design":"clinical trial","title":"Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease","title_match":true,"year":2023},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/omicsynth-an-open-multi-omic-community-resource-for-identifying-38181731","doi":"10.1016/j.ajhg.2023.12.006","journal":"American journal of human genetics","n_participants":null,"pmid":"38181731","source_url":"https://pubmed.ncbi.nlm.nih.gov/38181731/","study_design":null,"title":"omicSynth: An open multi-omic community resource for identifying druggable targets across neurodegenerative diseases","title_match":false,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/new-and-emerging-drug-therapies-for-alzheimer-disease-38962384","doi":"10.18773/austprescr.2024.021","journal":"Australian prescriber","n_participants":null,"pmid":"38962384","source_url":"https://pubmed.ncbi.nlm.nih.gov/38962384/","study_design":null,"title":"New and emerging drug therapies for Alzheimer disease","title_match":false,"year":2024},{"alzhub_score":34,"alzhub_url":"https://alzhub.org/study/how-promising-are-the-latest-monoclonal-antibodies-targeting-amyloid-38193477","doi":"10.1080/14728214.2024.2304059","journal":"Expert opinion on emerging drugs","n_participants":null,"pmid":"38193477","source_url":"https://pubmed.ncbi.nlm.nih.gov/38193477/","study_design":null,"title":"How promising are the latest monoclonal antibodies targeting amyloid-\u03b2 for the treatment of early Alzheimer's disease?","title_match":false,"year":2024},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/biomarkers-as-endpoints-in-clinical-trials-for-alzheimer-s-disease-38669547","doi":"10.3233/jad-240008","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"38669547","source_url":"https://pubmed.ncbi.nlm.nih.gov/38669547/","study_design":"clinical trial","title":"Biomarkers as Endpoints in Clinical Trials for Alzheimer's Disease","title_match":false,"year":2024},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/antiamyloid-treatment-for-dementia-concerns-outweigh-hopes-40511512","doi":"10.1097/yco.0000000000001021","journal":"Current opinion in psychiatry","n_participants":null,"pmid":"40511512","source_url":"https://pubmed.ncbi.nlm.nih.gov/40511512/","study_design":null,"title":"Antiamyloid treatment for dementia: concerns outweigh hopes","title_match":false,"year":2025},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/incidence-of-amyloid-related-imaging-abnormalities-and-health-41885326","doi":"10.18553/jmcp.2026.32.4.470","journal":"Journal of managed care & specialty pharmacy","n_participants":240,"pmid":"41885326","source_url":"https://pubmed.ncbi.nlm.nih.gov/41885326/","study_design":null,"title":"Incidence of amyloid-related imaging abnormalities and health resource utilization in patients with Alzheimer disease receiving monoclonal antibody treatments: A real-world evidence study","title_match":false,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/anti-amyloid-antibody-equilibrium-binding-to-a-aggregates-from-human-35ab99e8","doi":"10.1101/2025.05.20.654902","journal":"bioRxiv","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1101/2025.05.20.654902","study_design":"cross-sectional","title":"Anti-amyloid antibody equilibrium binding to A\u03b2 aggregates from human Alzheimer disease brain","title_match":false,"year":2025},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/exploring-natural-compounds-for-alzheimer-s-disease-virtual-screening-a3b419d0","doi":"10.20944/preprints202402.0232.v1","journal":"Preprints.org","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.20944/preprints202402.0232.v1","study_design":null,"title":"Exploring Natural Compounds for Alzheimer's Disease: Virtual Screening and Docking Study with KIBRA Protein","title_match":false,"year":2024},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/lecanemab-adoption-and-geographic-variation-among-patients-with-41433980","doi":"10.1002/alz70860_106870","journal":"Alzheimer s & Dementia","n_participants":2512,"pmid":"41433980","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12725693/","study_design":null,"title":"Lecanemab adoption and geographic variation among patients with diagnosis of mild cognitive impairment or Alzheimer's dementia in Medicare fee\u2010for\u2010service beneficiaries","title_match":true,"year":2025},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/amyloid-pet-signal-reduction-in-prior-aria-e-regions-after-41260674","doi":"10.3174/ajnr.a9111","journal":"American Journal of Neuroradiology","n_participants":null,"pmid":"41260674","source_url":"https://pubmed.ncbi.nlm.nih.gov/41260674/","study_design":null,"title":"\u03b2-Amyloid PET Signal Reduction in Prior ARIA-E Regions after Antiamyloid Therapy for Alzheimer Disease","title_match":false,"year":2025},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/brain-amyloid-plaque-levels-affect-clinical-progression-in-alzheimer-41543367","doi":"10.1002/psp4.70173","journal":"CPT Pharmacometrics & Systems Pharmacology","n_participants":null,"pmid":"41543367","source_url":"https://pubmed.ncbi.nlm.nih.gov/41543367/","study_design":"clinical trial","title":"Brain Amyloid Plaque Levels Affect Clinical Progression in Alzheimer Disease: Assessment of Amyloid PET and Change in CDR \u2010 SB Utilizing Semi\u2010Mechanistic Model","title_match":false,"year":2026},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/lecanemab-in-diad-6month-amyloid-pet-results-from-the-diantu001-trial-41447716","doi":"10.1002/alz70859_105303","journal":"Alzheimer s & Dementia","n_participants":97,"pmid":"41447716","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12740335/","study_design":null,"title":"Lecanemab in DIAD: 6\u2010Month Amyloid PET Results from the DIAN\u2010TU\u2010001 Trial","title_match":true,"year":2025},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/a-review-of-clinical-biomarker-insights-advances-in-diagnosis-and-5adb338a","doi":"10.25259/gjmpbu_38_2024","journal":"Global Journal of Medical Pharmaceutical and Biomedical Update","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.25259/gjmpbu_38_2024","study_design":null,"title":"A Review of Clinical Biomarker Insights: Advances in Diagnosis and Prognosis of Early Alzheimer","title_match":false,"year":2025},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/determining-eligibility-for-antiamyloid-treatments-using-blood-41442134","doi":"10.1002/alz70856_097511","journal":"Alzheimer s & Dementia","n_participants":4000,"pmid":"41442134","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12732564/","study_design":null,"title":"Determining eligibility for anti\u2010amyloid treatments using blood biomarkers","title_match":false,"year":2025},{"alzhub_score":51,"alzhub_url":"https://alzhub.org/study/dynamic-changes-in-plasma-biomarkers-of-alzheimer-s-disease-in-42785333","doi":"10.1016/s1474-4422(26)00284-x","journal":"The Lancet Neurology","n_participants":1312,"pmid":"42785333","source_url":"https://pubmed.ncbi.nlm.nih.gov/42785333/","study_design":"cohort study","title":"Dynamic changes in plasma biomarkers of Alzheimer's disease in patients treated with lecanemab: a longitudinal cohort study","title_match":true,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/relationship-between-apoe-genotype-status-and-imaging-features-in-41781178","doi":"10.3174/ajnr.a9056","journal":"American Journal of Neuroradiology","n_participants":85,"pmid":"41781178","source_url":"https://pubmed.ncbi.nlm.nih.gov/41781178/","study_design":null,"title":"Relationship between APOE Genotype Status and Imaging Features in Patients with Alzheimer Disease Being Considered for Antiamyloid \u03b2 Therapy","title_match":false,"year":2026},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/novel-drug-delivery-system-a-pandora-box-for-the-manage-ment-of-f13bd11e","doi":"10.4238/0fganh12","journal":"Genetics and Molecular Research","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.4238/0fganh12","study_design":null,"title":"NOVEL DRUG DELIVERY SYSTEM: A PANDORA BOX FOR THE MANAGE MENT OF ALZHEIMER NOVEL DRUG DELIVERY IN ALZHEIMER","title_match":false,"year":2026},{"alzhub_score":37,"alzhub_url":"https://alzhub.org/study/lecanemab-use-for-early-alzheimer-disease-in-canada-42373113","doi":"10.1503/cmaj.260193","journal":"Canadian Medical Association Journal","n_participants":null,"pmid":"42373113","source_url":"https://pubmed.ncbi.nlm.nih.gov/42373113/","study_design":null,"title":"Lecanemab use for early Alzheimer disease in Canada","title_match":true,"year":2026},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-in-early-alzheimer-disease-42784125","doi":"10.3390/neurolint18090171","journal":"Neurology International","n_participants":null,"pmid":"42784125","source_url":"https://pubmed.ncbi.nlm.nih.gov/42784125/","study_design":"meta-analysis","title":"Anti-Amyloid Monoclonal Antibodies in Early Alzheimer Disease: Lecanemab and Donanemab","title_match":true,"year":2026},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/anticuerpos-monoclonales-antiamiloide-y-enfermedad-de-alzheimer-d85edb6b","doi":"10.24875/kranion.m26000124","journal":"Kranion","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.24875/kranion.m26000124","study_design":null,"title":"Anticuerpos monoclonales antiamiloide y enfermedad de Alzheimer: \u00bfestamos preparados?","title_match":false,"year":2026},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/lecanemab-aducanumab-and-donanemab-bind-the-same-human-alzheimer-41435407","doi":"10.1002/alz70855_099914","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"41435407","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12726945/","study_design":null,"title":"Lecanemab, aducanumab, and donanemab bind the same human Alzheimer disease A\u03b2 aggregates at different epitopes","title_match":true,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/pet-guided-assessment-of-amyloid-clearance-and-outcomes-in-a-real-42055956","doi":"10.3174/ajnr.a9387","journal":"American Journal of Neuroradiology","n_participants":15,"pmid":"42055956","source_url":"https://pubmed.ncbi.nlm.nih.gov/42055956/","study_design":"longitudinal study","title":"PET-guided Assessment of Amyloid Clearance and Outcomes in a Real-World Cohort of Patients with Alzheimer Disease undergoing Anti-Amyloid Therapy","title_match":false,"year":2026},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/use-of-lecanemab-and-donanemab-in-the-canadian-healthcare-system-39893139","doi":"10.1016/j.tjpad.2025.100068","journal":"The Journal of Prevention of Alzheimer s Disease","n_participants":null,"pmid":"39893139","source_url":"https://pubmed.ncbi.nlm.nih.gov/39893139/","study_design":null,"title":"Use of lecanemab and donanemab in the Canadian healthcare system: Evidence, challenges, and areas for future research","title_match":true,"year":2025},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/long-term-surveillance-of-the-anti-amyloid-monoclonal-antibody-40217276","doi":"10.1186/s13195-025-01699-6","journal":"Alzheimer s Research & Therapy","n_participants":null,"pmid":"40217276","source_url":"https://pubmed.ncbi.nlm.nih.gov/40217276/","study_design":null,"title":"Long-term surveillance of the anti-amyloid monoclonal antibody lecanemab: rights and duties of pharmacovigilance","title_match":true,"year":2025},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/disparities-in-early-lecanemab-uptake-among-us-medicare-beneficiaries-40372759","doi":"10.1001/jamanetworkopen.2025.11711","journal":"JAMA Network Open","n_participants":null,"pmid":"40372759","source_url":"https://pubmed.ncbi.nlm.nih.gov/40372759/","study_design":"cross-sectional","title":"Disparities in Early Lecanemab Uptake Among US Medicare Beneficiaries","title_match":true,"year":2025},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/realworld-eligibility-for-antiamyloid-treatment-in-a-tertiary-memory-40506692","doi":"10.1002/alz.70375","journal":"Alzheimer s & Dementia","n_participants":1309,"pmid":"40506692","source_url":"https://pubmed.ncbi.nlm.nih.gov/40506692/","study_design":null,"title":"\u201cReal\u2010world\u201d eligibility for anti\u2010amyloid treatment in a tertiary memory clinic setting","title_match":false,"year":2025},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/krankheitsmodifizierende-therapie-mit-lecanemab-bei-fruher-alzheimer-41052542","doi":"10.1055/a-2681-4558","journal":"Fortschritte der Neurologie \u00b7 Psychiatrie","n_participants":null,"pmid":"41052542","source_url":"https://pubmed.ncbi.nlm.nih.gov/41052542/","study_design":null,"title":"Krankheitsmodifizierende Therapie mit Lecanemab bei fr\u00fcher Alzheimer-Demenz","title_match":true,"year":2025},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/changes-of-a-cerebral-cavernous-malformation-associated-with-40584633","doi":"10.1212/cpj.0000000000200508","journal":"Neurology Clinical Practice","n_participants":null,"pmid":"40584633","source_url":"https://pubmed.ncbi.nlm.nih.gov/40584633/","study_design":null,"title":"Changes of a Cerebral Cavernous Malformation Associated With Lecanemab Therapy in a Patient With Alzheimer Disease","title_match":true,"year":2025},{"alzhub_score":56,"alzhub_url":"https://alzhub.org/study/are-deep-white-matter-hyperintensities-associated-with-amyloid-41038644","doi":"10.3174/ajnr.a8822","journal":"American Journal of Neuroradiology","n_participants":27,"pmid":"41038644","source_url":"https://pubmed.ncbi.nlm.nih.gov/41038644/","study_design":"cohort study","title":"Are Deep White Matter Hyperintensities Associated with Amyloid-Related Imaging Abnormalities in Patients with Alzheimer Disease Treated with Lecanemab?","title_match":true,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/clinical-practice-outcomes-with-lecanemab-for-alzheimer-disease-42746606","doi":"10.1212/wn9.0000000000000121","journal":"Neurology Open Access","n_participants":null,"pmid":"42746606","source_url":"https://pubmed.ncbi.nlm.nih.gov/42746606/","study_design":null,"title":"Clinical Practice Outcomes With Lecanemab for Alzheimer Disease","title_match":true,"year":2026},{"alzhub_score":30,"alzhub_url":"https://alzhub.org/study/lecanemab-en-la-enfermedad-de-alzheimer-ab04d0ab","doi":"10.22379/anc.v41i2.1938","journal":"Acta neurol\u00f3gica colombiana","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.22379/anc.v41i2.1938","study_design":null,"title":"Lecanemab en la enfermedad de Alzheimer","title_match":true,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/treating-alzheimer-disease-with-antiamyloid-therapiesthe-real-world-40844810","doi":"10.1001/jama.2025.14180","journal":"JAMA","n_participants":null,"pmid":"40844810","source_url":"https://pubmed.ncbi.nlm.nih.gov/40844810/","study_design":null,"title":"Treating Alzheimer Disease With Antiamyloid Therapies\u2014The Real-World Experience Grows","title_match":false,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/evaluating-the-cost-effectiveness-of-pharmacological-therapy-in-40435868","doi":"10.1016/j.vhri.2025.101130","journal":"Value in Health Regional Issues","n_participants":null,"pmid":"40435868","source_url":"https://pubmed.ncbi.nlm.nih.gov/40435868/","study_design":null,"title":"Evaluating the Cost-Effectiveness of Pharmacological Therapy in Alzheimer Disease in Brazil","title_match":false,"year":2025},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/a-new-era-in-neuropharmacology-assessing-the-efficacy-and-safety-of-42084750","doi":"10.1007/s00415-026-13829-7","journal":"Journal of Neurology","n_participants":null,"pmid":"42084750","source_url":"https://pubmed.ncbi.nlm.nih.gov/42084750/","study_design":null,"title":"A new era in neuropharmacology: assessing the efficacy and safety of novel anti-amyloid and non-amyloid drug targets for Alzheimer's disease","title_match":false,"year":2026},{"alzhub_score":49,"alzhub_url":"https://alzhub.org/study/safety-of-lecanemab-after-6month-treatment-in-the-diantu001-trial-41447712","doi":"10.1002/alz70859_105304","journal":"Alzheimer s & Dementia","n_participants":97,"pmid":"41447712","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12740332/","study_design":null,"title":"Safety of Lecanemab After 6\u2010Month Treatment in the DIAN\u2010TU\u2010001 Trial","title_match":true,"year":2025},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/lecanemab-binds-to-transgenic-mouse-modelderived-amyloid-fibril-40495448","doi":"10.1111/nan.70022","journal":"Neuropathology and Applied Neurobiology","n_participants":null,"pmid":"40495448","source_url":"https://pubmed.ncbi.nlm.nih.gov/40495448/","study_design":null,"title":"Lecanemab Binds to Transgenic Mouse Model\u2010Derived Amyloid\u2010\u03b2 Fibril Structures Resembling Alzheimer's Disease Type I, Type II and Arctic Folds","title_match":true,"year":2025},{"alzhub_score":32,"alzhub_url":"https://alzhub.org/study/both-amyloid-and-tau-assessments-are-desired-before-initiating-40108731","doi":"10.1097/rlu.0000000000005842","journal":"Clinical Nuclear Medicine","n_participants":null,"pmid":"40108731","source_url":"https://pubmed.ncbi.nlm.nih.gov/40108731/","study_design":"clinical trial","title":"Both Amyloid and Tau Assessments Are Desired Before Initiating Disease-modifying Therapy for Alzheimer Disease: Three Real-world Cases","title_match":false,"year":2025},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/real-world-safety-profile-of-lecanemab-a-disproportionality-analysis-cbaaba6e","doi":"10.1016/j.japhar.2025.100015","journal":"JAPhA Pharmacotherapy","n_participants":1307937,"pmid":null,"source_url":"https://doi.org/10.1016/j.japhar.2025.100015","study_design":null,"title":"Real-world safety profile of lecanemab: A disproportionality analysis of adverse events in the FDA adverse event reporting system","title_match":true,"year":2025},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-and-amyloid-related-imaging-4ee39e2d","doi":"10.5281/zenodo.22310606","journal":"Zenodo (CERN European Organization for Nuclear Research)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.22310606","study_design":"narrative review","title":"Anti-Amyloid Monoclonal Antibodies and Amyloid-Related Imaging Abnormalities in Early Alzheimer Disease","title_match":false,"year":2026},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-and-amyloid-related-imaging-95d6b60f","doi":"10.5281/zenodo.22310607","journal":"Zenodo (CERN European Organization for Nuclear Research)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.22310607","study_design":"narrative review","title":"Anti-Amyloid Monoclonal Antibodies and Amyloid-Related Imaging Abnormalities in Early Alzheimer Disease","title_match":false,"year":2026},{"alzhub_score":29,"alzhub_url":"https://alzhub.org/study/terapias-emergentes-para-la-enfermedad-de-alzheimer-revision-3c483de3","doi":"10.61368/r.s.d.h.v6i2.661","journal":"Revista Cient\u00edfica de Salud y Desarrollo Humano","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.61368/r.s.d.h.v6i2.661","study_design":null,"title":"Terapias emergentes para la enfermedad de Alzheimer: revisi\u00f3n sistem\u00e1tica de anticuerpos anti-amiloide y mecanismos alternativos","title_match":false,"year":2025},{"alzhub_score":31,"alzhub_url":"https://alzhub.org/study/lecanemab-donanemab-and-emerging-disease-modifying-therapies-for-d453d052","doi":"10.5281/zenodo.17615265","journal":"International Journal of Science and Research Archive","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.17615265","study_design":"narrative review","title":"Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in Canada","title_match":true,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/lecanemab-donanemab-and-emerging-disease-modifying-therapies-for-08ace6f7","doi":"10.5281/zenodo.17615266","journal":"International Journal of Science and Research Archive","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.17615266","study_design":"narrative review","title":"Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in Canada","title_match":true,"year":2025},{"alzhub_score":31,"alzhub_url":"https://alzhub.org/study/lecanemab-donanemab-and-emerging-disease-modifying-therapies-for-1b2f6657","doi":"10.30574/ijsra.2025.17.1.2929","journal":"International Journal of Science and Research Archive","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.30574/ijsra.2025.17.1.2929","study_design":"narrative review","title":"Lecanemab, Donanemab, and Emerging Disease Modifying Therapies for Alzheimer Disease: Clinical Evidence and Primary Care Implications in Canada","title_match":true,"year":2025},{"alzhub_score":44,"alzhub_url":"https://alzhub.org/study/monoclonal-antibodies-for-treatment-alzheimer-s-disease-12954b56","doi":"10.31393/reports-vnmedical-2025-29(4)-29","journal":"Reports of Vinnytsia National Medical University","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.31393/reports-vnmedical-2025-29(4)-29","study_design":"systematic review","title":"Monoclonal antibodies for treatment Alzheimer`s disease","title_match":false,"year":2025},{"alzhub_score":26,"alzhub_url":"https://alzhub.org/study/bildgebungsanomalien-bei-alzheimer-therapie-mit-lecanemab-b85e6325","doi":"10.1055/a-2788-0873","journal":"Neuroradiologie Scan","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1055/a-2788-0873","study_design":null,"title":"Bildgebungsanomalien bei Alzheimer-Therapie mit Lecanemab","title_match":true,"year":2026},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/lecanemab-and-donanemab-combination-therapy-for-alzheimers-disease-41773886","doi":"10.1097/wad.0000000000000711","journal":"Alzheimer Disease & Associated Disorders","n_participants":null,"pmid":"41773886","source_url":"https://pubmed.ncbi.nlm.nih.gov/41773886/","study_design":null,"title":"Lecanemab and Donanemab Combination Therapy for Alzheimer\u2019s Disease-The Cocktail May Work Even Better Together","title_match":true,"year":2026},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/characterization-of-the-anti-alzheimer-drug-lecanemab-by-mass-42368154","doi":"10.1021/acsomega.6c02666","journal":"ACS Omega","n_participants":null,"pmid":"42368154","source_url":"https://pubmed.ncbi.nlm.nih.gov/42368154/","study_design":null,"title":"Characterization of the Anti-Alzheimer Drug Lecanemab by Mass Spectrometry","title_match":true,"year":2026},{"alzhub_score":25,"alzhub_url":"https://alzhub.org/study/lecanemab-bei-alzheimer-krankheit-fruhe-therapie-ist-sicher-eac9be64","doi":"10.1055/a-2700-9104","journal":"Fortschritte der Neurologie \u00b7 Psychiatrie","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1055/a-2700-9104","study_design":null,"title":"Lecanemab bei Alzheimer-Krankheit: Fr\u00fche Therapie ist sicher","title_match":true,"year":2025},{"alzhub_score":33,"alzhub_url":"https://alzhub.org/study/anti-amyloid-treatment-in-alzheimer-disease-updated-implications-for-42688139","doi":"10.3389/fneur.2026.1889769","journal":"Frontiers in Neurology","n_participants":null,"pmid":"42688139","source_url":"https://pubmed.ncbi.nlm.nih.gov/42688139/","study_design":null,"title":"Anti-amyloid treatment in Alzheimer disease: updated implications for patients with cerebral amyloid angiopathy and other cerebrovascular conditions","title_match":false,"year":2026},{"alzhub_score":31,"alzhub_url":"https://alzhub.org/study/therapeutic-monoclonal-antibodies-targeting-amyloid-beta-in-alzheimer-0a449f11","doi":"10.1186/s13064-026-00295-0","journal":"Discover Neuroscience","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1186/s13064-026-00295-0","study_design":null,"title":"Therapeutic monoclonal antibodies targeting amyloid beta in Alzheimer disease current evidence clinical outcomes limitations and future directions","title_match":false,"year":2026},{"alzhub_score":51,"alzhub_url":"https://alzhub.org/study/assessing-the-clinical-meaningfulness-of-slowing-cdrsb-progression-39949872","doi":"10.1002/trc2.70033","journal":"Alzheimer s & Dementia Translational Research & Clinical Interventions","n_participants":282,"pmid":"39949872","source_url":"https://pubmed.ncbi.nlm.nih.gov/39949872/","study_design":null,"title":"Assessing the clinical meaningfulness of slowing CDR\u2010SB progression with disease\u2010modifying therapies for Alzheimer's disease","title_match":false,"year":2025},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/lecanemab-leqembi-25dfc5ad","doi":"10.51731/cjht.2026.1514","journal":"Canadian Journal of Health Technologies","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.51731/cjht.2026.1514","study_design":null,"title":"Lecanemab (Leqembi)","title_match":true,"year":2026},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/lecanemab-como-tratamiento-en-el-deterioro-cognitivo-de-pacientes-con-d42e1b7d","doi":"10.35366/119479","journal":"Acta M\u00e9dica Grupo \u00c1ngeles","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.35366/119479","study_design":null,"title":"Lecanemab como tratamiento en el deterioro cognitivo de pacientes con Alzheimer","title_match":true,"year":2025},{"alzhub_score":29,"alzhub_url":"https://alzhub.org/study/lecanemab-e-la-malattia-di-alzheimer-perusini-tra-speranze-40637522","doi":"10.1701/4530.45309","journal":"Recenti Progressi in Medicina","n_participants":null,"pmid":"40637522","source_url":"https://pubmed.ncbi.nlm.nih.gov/40637522/","study_design":null,"title":"Lecanemab e la malattia di Alzheimer-Perusini: tra speranze terapeutiche e sfide regolatorie","title_match":true,"year":2025},{"alzhub_score":33,"alzhub_url":"https://alzhub.org/study/antiamyloid-antibodies-in-europe-where-are-we-now-41810890","doi":"10.1002/bcp.70526","journal":"British Journal of Clinical Pharmacology","n_participants":null,"pmid":"41810890","source_url":"https://pubmed.ncbi.nlm.nih.gov/41810890/","study_design":"clinical trial","title":"Anti\u2010amyloid antibodies in Europe: Where are we now?","title_match":false,"year":2026},{"alzhub_score":26,"alzhub_url":"https://alzhub.org/study/transkript-zur-episode-lecanemab-52ec276c","doi":"10.69156/trx.001/2025.10.00152","journal":"EvidenzUpdate","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.69156/trx.001/2025.10.00152","study_design":null,"title":"Transkript zur Episode \u201eLecanemab\u201c","title_match":true,"year":2025},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/eficacia-del-lecanemab-en-el-tratamiento-de-la-enfermedad-de-cf778e0b","doi":"10.5281/zenodo.22756412","journal":"Zenodo (CERN European Organization for Nuclear Research)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.22756412","study_design":null,"title":"Eficacia del lecanemab en el tratamiento de la Enfermedad de Alzheimer: revisi\u00f3n de la literatura (2015-2025)","title_match":true,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/eficacia-del-lecanemab-en-el-tratamiento-de-la-enfermedad-de-ee62b24d","doi":"10.5281/zenodo.22756413","journal":"Zenodo (CERN European Organization for Nuclear Research)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.22756413","study_design":null,"title":"Eficacia del lecanemab en el tratamiento de la Enfermedad de Alzheimer: revisi\u00f3n de la literatura (2015-2025)","title_match":true,"year":2026},{"alzhub_score":51,"alzhub_url":"https://alzhub.org/study/alzheimer-s-disease-neuroimaging-initiative-two-decades-of-pioneering-39760440","doi":"10.1002/alz.14186","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"39760440","source_url":"https://pubmed.ncbi.nlm.nih.gov/39760440/","study_design":"longitudinal study","title":"Alzheimer's Disease Neuroimaging Initiative: Two decades of pioneering Alzheimer's disease research and future directions","title_match":false,"year":2025},{"alzhub_score":26,"alzhub_url":"https://alzhub.org/study/lecanemab-wirksamkeit-beruht-auf-dem-fc-fragment-des-antikorpers-0681bd63","doi":"10.1055/a-2861-9919","journal":"Fortschritte der Neurologie \u00b7 Psychiatrie","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1055/a-2861-9919","study_design":null,"title":"Lecanemab: Wirksamkeit beruht auf dem Fc-Fragment des Antik\u00f6rpers","title_match":true,"year":2026},{"alzhub_score":29,"alzhub_url":"https://alzhub.org/study/doctor-if-it-were-you-which-would-you-choose-navigating-personal-42318437","doi":"10.1002/dad2.70373","journal":"Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring","n_participants":null,"pmid":"42318437","source_url":"https://pubmed.ncbi.nlm.nih.gov/42318437/","study_design":null,"title":"\u201cDoctor, if it were you, which would you choose?\u201d: Navigating personal preference questions in anti\u2010amyloid immunotherapy selection","title_match":false,"year":2026},{"alzhub_score":30,"alzhub_url":"https://alzhub.org/study/determinants-of-treatment-willingness-and-willingness-to-pay-for-40955711","doi":"10.1097/wad.0000000000000689","journal":"Alzheimer Disease & Associated Disorders","n_participants":null,"pmid":"40955711","source_url":"https://pubmed.ncbi.nlm.nih.gov/40955711/","study_design":null,"title":"Determinants of Treatment Willingness and Willingness-to-Pay for Lecanemab in China","title_match":true,"year":2025},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/nieuwe-geneesmiddelen-bij-alzheimer-update-69d2f1b5","doi":"10.35351/gebu.nl.2025.11.30","journal":"Geneesmiddelenbulletin","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.35351/gebu.nl.2025.11.30","study_design":null,"title":"Nieuwe geneesmiddelen bij Alzheimer - Update","title_match":false,"year":2025},{"alzhub_score":25,"alzhub_url":"https://alzhub.org/study/netzwerkmetaanalyse-zu-neuen-therapieoptionen-bei-alzheimer-demenz-0b1099e7","doi":"10.1055/a-2523-9611","journal":"Fortschritte der Neurologie \u00b7 Psychiatrie","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1055/a-2523-9611","study_design":null,"title":"Netzwerkmetaanalyse zu neuen Therapieoptionen bei Alzheimer Demenz","title_match":false,"year":2025},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/neue-alzheimer-therapien-vortrag-zu-aria-fur-eine-sichere-mrt-41130241","doi":"10.1055/a-2690-5210","journal":"R\u00f6Fo - Fortschritte auf dem Gebiet der R\u00f6ntgenstrahlen und der bildgebenden Verfahren","n_participants":null,"pmid":"41130241","source_url":"https://pubmed.ncbi.nlm.nih.gov/41130241/","study_design":null,"title":"Neue Alzheimer-Therapien: Vortrag zu ARIA f\u00fcr eine sichere MRT-Diagnostik","title_match":false,"year":2025},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/anticorpos-anti-amiloide-no-tratamento-da-doenca-de-alzheimer-uma-b2f98913","doi":"10.61411/rsc202593118","journal":"Revista Sociedade Cient\u00edfica","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.61411/rsc202593118","study_design":null,"title":"Anticorpos anti-amiloide no tratamento da Doen\u00e7a de Alzheimer: uma revis\u00e3o narrativa","title_match":false,"year":2025},{"alzhub_score":28,"alzhub_url":"https://alzhub.org/study/interview-interview-zum-thema-neue-alzheimer-therapien-warum-radiolog-41130242","doi":"10.1055/a-2690-4869","journal":"R\u00f6Fo - Fortschritte auf dem Gebiet der R\u00f6ntgenstrahlen und der bildgebenden Verfahren","n_participants":null,"pmid":"41130242","source_url":"https://pubmed.ncbi.nlm.nih.gov/41130242/","study_design":null,"title":"Interview \u2013 Interview zum Thema: Neue Alzheimer-Therapien: Warum Radiolog:innen ARIA kennen m\u00fcssen","title_match":false,"year":2025},{"alzhub_score":26,"alzhub_url":"https://alzhub.org/study/avancos-na-doenca-de-alzheimer-diagnostico-precoce-biomarcadores-e-3d634112","doi":"10.55684/2025.83.s1.e00009","journal":"BioSCIENCE","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.55684/2025.83.s1.e00009","study_design":null,"title":"Avan\u00e7os na doen\u00e7a de Alzheimer: diagn\u00f3stico precoce, biomarcadores e perspectivas futuras","title_match":false,"year":2025},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/lecanemab-autorizado-para-tratamiento-del-alzheimer-en-pacientes-que-d2104574","doi":"10.63105/pam8","journal":"Panorama actual del medicamento","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.63105/pam8","study_design":null,"title":"Lecanemab autorizado para tratamiento del Alzh\u00e9imer en pacientes que tienen una o ninguna copia de ApoE4: una reacci\u00f3n adversa grave limita su uso","title_match":true,"year":2025},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/alzheimer-e-a-evolucao-do-tratamento-na-ultima-decada-uma-revisao-de-2e796461","doi":"10.5281/zenodo.17193516","journal":"JNT - Facit Business and Technology Journal","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.17193516","study_design":null,"title":"ALZHEIMER E A EVOLU\u00c7\u00c3O DO TRATAMENTO NA \u00daLTIMA D\u00c9CADA: UMA REVIS\u00c3O DE LITERATURA","title_match":false,"year":2025},{"alzhub_score":39,"alzhub_url":"https://alzhub.org/study/alzheimer-e-a-evolucao-do-tratamento-na-ultima-decada-uma-revisao-de-92b69fc6","doi":"10.5281/zenodo.17193517","journal":"JNT - Facit Business and Technology Journal","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.5281/zenodo.17193517","study_design":null,"title":"ALZHEIMER E A EVOLU\u00c7\u00c3O DO TRATAMENTO NA \u00daLTIMA D\u00c9CADA: UMA REVIS\u00c3O DE LITERATURA","title_match":false,"year":2025},{"alzhub_score":29,"alzhub_url":"https://alzhub.org/study/en-respuesta-a-avances-y-controversias-de-los-tratamientos-de-la-42435702","doi":"10.1016/j.aprim.2026.103570","journal":"Atenci\u00f3n Primaria","n_participants":null,"pmid":"42435702","source_url":"https://pubmed.ncbi.nlm.nih.gov/42435702/","study_design":null,"title":"En respuesta a \u00abAvances y controversias de los tratamientos de la enfermedad de Alzheimer\u00bb","title_match":false,"year":2026},{"alzhub_score":26,"alzhub_url":"https://alzhub.org/study/biomarcadores-de-laboratorio-en-la-enfermedad-de-alzheimer-avances-520c3a35","doi":"10.24875/kranion.m25000107","journal":"Kranion","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.24875/kranion.m25000107","study_design":null,"title":"Biomarcadores de laboratorio en la enfermedad de Alzheimer: avances recientes e implantaci\u00f3n en un hospital de tercer nivel","title_match":false,"year":2025},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/transport-pathways-across-the-blood-brain-barrier-for-waste-clearance-42143322","doi":"10.1186/s12987-026-00812-7","journal":"Fluids and Barriers of the CNS","n_participants":null,"pmid":"42143322","source_url":"https://pubmed.ncbi.nlm.nih.gov/42143322/","study_design":null,"title":"Transport pathways across the blood-brain barrier for waste clearance and drug delivery","title_match":false,"year":2026},{"alzhub_score":44,"alzhub_url":"https://alzhub.org/study/antiamyloid-therapy-and-cerebral-blood-flow-changes-on-mri-a-39805666","doi":"10.3174/ajnr.a8654","journal":"American Journal of Neuroradiology","n_participants":null,"pmid":"39805666","source_url":"https://pubmed.ncbi.nlm.nih.gov/39805666/","study_design":"longitudinal study","title":"Antiamyloid Therapy and Cerebral Blood Flow Changes on MRI: A Potential Longitudinal Biomarker of Treatment Response?","title_match":false,"year":2025},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/redefining-alzheimers-disease-through-modern-biotechnology-from-92541794","doi":"10.65035/w1y9ey43","journal":"Journal of medical & health sciences review.","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.65035/w1y9ey43","study_design":null,"title":"REDEFINING ALZHEIMER\u2019S DISEASE THROUGH MODERN BIOTECHNOLOGY; FROM MOLECULAR PATHOGENESIS TO INNOVATIVE THERAPEUTICS AND DIAGNOSTIC FRONTIERS","title_match":false,"year":2025},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/advances-in-immunotherapy-for-alzheimer-s-disease-2020-2023-a-aa1cc3c7","doi":"10.12775/jehs.2025.80.49304","journal":"Journal of Education Health and Sport","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.12775/jehs.2025.80.49304","study_design":null,"title":"Advances in immunotherapy for Alzheimer's Disease 2020-2023 \u2013 a literature review","title_match":false,"year":2025},{"alzhub_score":27,"alzhub_url":"https://alzhub.org/study/terapia-anti-amiloide-y-enfermedad-cerebrovascular-nuevos-retos-para-7db0e4e9","doi":"10.22379/anc.2188","journal":"Acta neurol\u00f3gica colombiana","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.22379/anc.2188","study_design":null,"title":"Terapia anti \u03b2-amiloide y enfermedad cerebrovascular: nuevos retos para la neurolog\u00eda vascular","title_match":false,"year":2026},{"alzhub_score":26,"alzhub_url":"https://alzhub.org/study/model-of-the-impact-of-pharmacological-and-non-pharmacological-f695fc6b","doi":"10.54114/ingeniosv12i1.10262","journal":"[in]genio revista de investigaci\u00f3n y labor creativa","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.54114/ingeniosv12i1.10262","study_design":null,"title":"Model of the Impact of Pharmacological and Non-pharmacological Treatment of Alzheimer\u2019s Disease","title_match":false,"year":2025},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/baseline-imaging-characteristics-of-participants-in-the-phase-ii-iii-41447186","doi":"10.1002/alz70859_105301","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"41447186","source_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12739784/","study_design":null,"title":"Baseline Imaging Characteristics of Participants in the Phase II/III DIAN\u2010TU\u2010001 Tau NexGen Trial for Dominantly Inherited Alzheimer\u2019s Disease","title_match":false,"year":2025},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/early-alzheimers-disease-mild-cognitive-impairment-or-mild-dementia-40887393","doi":"10.1016/j.tjpad.2025.100362","journal":"The Journal of Prevention of Alzheimer s Disease","n_participants":null,"pmid":"40887393","source_url":"https://pubmed.ncbi.nlm.nih.gov/40887393/","study_design":"narrative review","title":"Early Alzheimer\u2019s disease (mild cognitive impairment or mild dementia): Prevalence, diagnostics, treatment options, and guidelines in Asia, Australasia, and Pacific nations countries","title_match":false,"year":2025},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/clinical-progression-on-cdrsb-progressionfree-time-at-each-0-5-unit-40911712","doi":"10.1002/alz.70643","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"40911712","source_url":"https://pubmed.ncbi.nlm.nih.gov/40911712/","study_design":"open-label trial","title":"Clinical progression on CDR\u2010SB\u00a9: Progression\u2010free time at each 0.5 unit level in dominantly inherited and sporadic Alzheimer's disease populations","title_match":false,"year":2025},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/real-world-clinical-practice-of-lecanemab-at-pumch-dementia-cohort-41520099","doi":"10.1186/s13195-025-01943-z","journal":"Alzheimer s Research & Therapy","n_participants":42,"pmid":"41520099","source_url":"https://pubmed.ncbi.nlm.nih.gov/41520099/","study_design":null,"title":"Real world clinical practice of lecanemab at PUMCH dementia cohort: focus on dynamic imaging and biomarker evolution","title_match":true,"year":2026},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/safety-and-effectiveness-of-lecanemab-in-chinese-patients-with-early-41069006","doi":"10.1097/cm9.0000000000003888","journal":"Chinese Medical Journal","n_participants":64,"pmid":"41069006","source_url":"https://pubmed.ncbi.nlm.nih.gov/41069006/","study_design":null,"title":"Safety and effectiveness of lecanemab in Chinese patients with early Alzheimer\u2019s disease: Evidence from a multidimensional real-world study","title_match":true,"year":2025},{"alzhub_score":58,"alzhub_url":"https://alzhub.org/study/clarity-ad-asian-regional-analysis-of-a-phase-iii-trial-of-lecanemab-40189473","doi":"10.1016/j.tjpad.2025.100160","journal":"The Journal of Prevention of Alzheimer s Disease","n_participants":294,"pmid":"40189473","source_url":"https://pubmed.ncbi.nlm.nih.gov/40189473/","study_design":"clinical trial","title":"Clarity AD: Asian regional analysis of a phase III trial of lecanemab in early Alzheimer's disease","title_match":true,"year":2025},{"alzhub_score":32,"alzhub_url":"https://alzhub.org/study/neuroinflammation-and-progress-in-clinical-trials-for-the-treatment-1ee39399","doi":"10.36922/imo025050007","journal":"Innovative Medicines & Omics","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.36922/imo025050007","study_design":null,"title":"Neuroinflammation and progress in clinical trials for the treatment of Alzheimer\u2019s disease and related dementias: An update","title_match":false,"year":2025},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/amyloid-solutions-lecanemab-gantenerumab-and-donanemab-in-the-2abd646d","doi":"10.1186/s41983-025-00968-3","journal":"The Egyptian Journal of Neurology Psychiatry and Neurosurgery","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.1186/s41983-025-00968-3","study_design":null,"title":"Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease","title_match":true,"year":2025},{"alzhub_score":55,"alzhub_url":"https://alzhub.org/study/current-advances-and-unmet-needs-in-alzheimer-s-disease-trials-for-40528298","doi":"10.1002/alz.70258","journal":"Alzheimer s & Dementia","n_participants":null,"pmid":"40528298","source_url":"https://pubmed.ncbi.nlm.nih.gov/40528298/","study_design":"longitudinal study","title":"Current advances and unmet needs in Alzheimer's disease trials for individuals with Down syndrome: Navigating new therapeutic frontiers","title_match":false,"year":2025},{"alzhub_score":34,"alzhub_url":"https://alzhub.org/study/alzheimers-disease-basics-we-all-should-know-40639927","doi":"10.1080/01616412.2025.2529560","journal":"Neurological Research","n_participants":null,"pmid":"40639927","source_url":"https://pubmed.ncbi.nlm.nih.gov/40639927/","study_design":null,"title":"Alzheimer\u2019s disease basics: we all should know","title_match":false,"year":2025},{"alzhub_score":49,"alzhub_url":"https://alzhub.org/study/a-2025-update-on-treatment-strategies-for-the-alzheimers-disease-40442885","doi":"10.1097/jcma.0000000000001252","journal":"Journal of the Chinese Medical Association","n_participants":null,"pmid":"40442885","source_url":"https://pubmed.ncbi.nlm.nih.gov/40442885/","study_design":null,"title":"A 2025 update on treatment strategies for the Alzheimer\u2019s disease spectrum","title_match":false,"year":2025},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/drug-drug-interaction-signals-between-anti-amyloid-antibodies-and-ba303595","doi":"10.64898/2026.09.08.26362402","journal":"medRxiv (preprint)","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.64898/2026.09.08.26362402","study_design":null,"title":"Drug-Drug Interaction Signals Between Anti-Amyloid-\u03b2 Antibodies and Antithrombotic Drugs for Amyloid-Related Imaging Abnormalities and Intracranial Hemorrhage: A FAERS Disproportionality Analysis","title_match":false,"year":2026},{"alzhub_score":26,"alzhub_url":"https://alzhub.org/study/the-missing-improvers-tau-pathology-neuroplasticity-and-the-case-for-42594414","doi":"10.1016/j.tjpad.2026.100653","journal":"The journal of prevention of Alzheimer's disease","n_participants":null,"pmid":"42594414","source_url":"https://pubmed.ncbi.nlm.nih.gov/42594414/","study_design":"post-hoc analysis","title":"The missing improvers: Tau pathology, neuroplasticity, and the case for tau-informed patient selection before amyloid immunotherapy","title_match":false,"year":2026},{"alzhub_score":37,"alzhub_url":"https://alzhub.org/study/real-world-safety-and-implementation-challenges-of-lecanemab-therapy-42449395","doi":"10.1186/s13195-026-02141-1","journal":"Alzheimer's research & therapy","n_participants":112,"pmid":"42449395","source_url":"https://pubmed.ncbi.nlm.nih.gov/42449395/","study_design":null,"title":"Real-world safety and implementation challenges of lecanemab therapy for Alzheimer's disease in South Korea: a single-center experience","title_match":true,"year":2026},{"alzhub_score":38,"alzhub_url":"https://alzhub.org/study/equity-and-budget-challenges-associated-with-the-employment-of-anti-42306480","doi":"10.1016/j.jarlif.2026.100076","journal":"JAR life","n_participants":42000,"pmid":"42306480","source_url":"https://pubmed.ncbi.nlm.nih.gov/42306480/","study_design":null,"title":"Equity and budget challenges associated with the employment of anti-amyloid monoclonal antibodies for early Alzheimer's Disease in Italy: A scenario analysis","title_match":false,"year":2026},{"alzhub_score":35,"alzhub_url":"https://alzhub.org/study/implementation-and-service-impact-of-anti-amyloid-therapy-in-a-42019137","doi":"10.1016/j.genhosppsych.2026.04.006","journal":"General hospital psychiatry","n_participants":null,"pmid":"42019137","source_url":"https://pubmed.ncbi.nlm.nih.gov/42019137/","study_design":null,"title":"Implementation and service impact of anti-amyloid therapy in a psychiatry-led dementia care program: Real-world evidence from a Japanese regional dementia center","title_match":false,"year":2026},{"alzhub_score":44,"alzhub_url":"https://alzhub.org/study/lecanemab-therapy-use-patterns-for-alzheimer-s-disease-among-early-41139687","doi":"10.1111/jgs.70010","journal":"Journal of the American Geriatrics Society","n_participants":137,"pmid":"41139687","source_url":"https://pubmed.ncbi.nlm.nih.gov/41139687/","study_design":null,"title":"Lecanemab Therapy Use Patterns for Alzheimer's Disease Among Early Initiators in a Large National Health Plan","title_match":true,"year":2025},{"alzhub_score":56,"alzhub_url":"https://alzhub.org/study/real-world-lecanemab-adoption-in-japan-1-year-after-launch-insights-41114448","doi":"10.1002/alz.70652","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":6000,"pmid":"41114448","source_url":"https://pubmed.ncbi.nlm.nih.gov/41114448/","study_design":null,"title":"Real-world lecanemab adoption in Japan 1 year after launch: Insights from 311 specialists on infrastructure and reimbursement barriers","title_match":true,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/long-term-value-of-lecanemab-to-individuals-and-families-40895811","doi":"10.1002/trc2.70151","journal":"Alzheimer's & dementia (New York, N. Y.)","n_participants":null,"pmid":"40895811","source_url":"https://pubmed.ncbi.nlm.nih.gov/40895811/","study_design":null,"title":"Long-term value of lecanemab to individuals and families","title_match":true,"year":2025},{"alzhub_score":56,"alzhub_url":"https://alzhub.org/study/practical-guide-of-the-korean-association-for-geriatric-psychiatry-to-40696527","doi":"10.3346/jkms.2025.40.e215","journal":"Journal of Korean medical science","n_participants":null,"pmid":"40696527","source_url":"https://pubmed.ncbi.nlm.nih.gov/40696527/","study_design":"randomized controlled trial","title":"Practical Guide of the Korean Association for Geriatric Psychiatry to Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer's Disease: Focused on Lecanemab","title_match":true,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/new-ipecad-open-source-model-framework-for-the-health-technology-39094686","doi":"10.1016/j.jval.2024.07.009","journal":"Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research","n_participants":null,"pmid":"39094686","source_url":"https://pubmed.ncbi.nlm.nih.gov/39094686/","study_design":null,"title":"New IPECAD Open-Source Model Framework for the Health Technology Assessment of Early Alzheimer's Disease Treatment: Development and Use Cases","title_match":false,"year":2025},{"alzhub_score":51,"alzhub_url":"https://alzhub.org/study/lecanemab-appropriate-use-recommendations-37357276","doi":"10.14283/jpad.2023.30","journal":"The Journal of Prevention of Alzheimer s Disease","n_participants":null,"pmid":"37357276","source_url":"https://pubmed.ncbi.nlm.nih.gov/37357276/","study_design":null,"title":"Lecanemab: Appropriate Use Recommendations","title_match":true,"year":2023},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/the-ahead-3-45-study-design-of-a-prevention-trial-for-alzheimer-s-35971310","doi":"10.1002/alz.12748","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"35971310","source_url":"https://pubmed.ncbi.nlm.nih.gov/35971310/","study_design":"clinical trial","title":"The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease","title_match":false,"year":2023},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/aducanumab-gantenerumab-ban2401-and-alz-801-the-first-wave-of-amyloid-32787971","doi":"10.1186/s13195-020-00663-w","journal":"Alzheimer's research & therapy","n_participants":null,"pmid":"32787971","source_url":"https://pubmed.ncbi.nlm.nih.gov/32787971/","study_design":"clinical trial","title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval","title_match":true,"year":2020},{"alzhub_score":81,"alzhub_url":"https://alzhub.org/study/lecanemab-in-patients-with-early-alzheimer-s-disease-detailed-results-36544184","doi":"10.1186/s13195-022-01124-2","journal":"Alzheimer's research & therapy","n_participants":856,"pmid":"36544184","source_url":"https://pubmed.ncbi.nlm.nih.gov/36544184/","study_design":"open-label trial","title":"Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study","title_match":true,"year":2022},{"alzhub_score":81,"alzhub_url":"https://alzhub.org/study/the-fda-approved-anti-amyloid-monoclonal-antibodies-for-the-treatment-38017568","doi":"10.1186/s40001-023-01512-w","journal":"European journal of medical research","n_participants":4471,"pmid":"38017568","source_url":"https://pubmed.ncbi.nlm.nih.gov/38017568/","study_design":"systematic review","title":"The FDA-approved anti-amyloid-\u03b2 monoclonal antibodies for the treatment of Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials","title_match":false,"year":2023},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/accelerating-alzheimer-s-therapeutic-development-the-past-and-future-37848035","doi":"10.1016/j.cell.2023.09.023","journal":"Cell","n_participants":null,"pmid":"37848035","source_url":"https://pubmed.ncbi.nlm.nih.gov/37848035/","study_design":"clinical trial","title":"Accelerating Alzheimer's therapeutic development: The past and future of clinical trials","title_match":false,"year":2023},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-for-the-treatment-of-alzheimer-s-37955845","doi":"10.1007/s40259-023-00633-2","journal":"BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy","n_participants":null,"pmid":"37955845","source_url":"https://pubmed.ncbi.nlm.nih.gov/37955845/","study_design":null,"title":"Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer's Disease","title_match":false,"year":2024},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/recent-advances-in-alzheimer-s-disease-mechanisms-clinical-trials-and-39174535","doi":"10.1038/s41392-024-01911-3","journal":"Signal transduction and targeted therapy","n_participants":null,"pmid":"39174535","source_url":"https://pubmed.ncbi.nlm.nih.gov/39174535/","study_design":null,"title":"Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/lecanemab-aducanumab-and-gantenerumab-binding-profiles-to-different-36253511","doi":"10.1007/s13311-022-01308-6","journal":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","n_participants":null,"pmid":"36253511","source_url":"https://pubmed.ncbi.nlm.nih.gov/36253511/","study_design":null,"title":"Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease","title_match":true,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/impact-of-anti-amyloid-monoclonal-antibodies-on-the-pathology-and-35493943","doi":"10.3389/fnagi.2022.870517","journal":"Frontiers in aging neuroscience","n_participants":null,"pmid":"35493943","source_url":"https://pubmed.ncbi.nlm.nih.gov/35493943/","study_design":null,"title":"Impact of Anti-amyloid-\u03b2 Monoclonal Antibodies on the Pathology and Clinical Profile of Alzheimer's Disease: A Focus on Aducanumab and Lecanemab","title_match":true,"year":2022},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-are-transformative-treatments-that-37060386","doi":"10.1007/s40265-023-01858-9","journal":"Drugs","n_participants":null,"pmid":"37060386","source_url":"https://pubmed.ncbi.nlm.nih.gov/37060386/","study_design":null,"title":"Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics","title_match":false,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/neurotoxic-soluble-amyloid-oligomers-drive-alzheimer-s-pathogenesis-34198582","doi":"10.3390/ijms22126355","journal":"International journal of molecular sciences","n_participants":null,"pmid":"34198582","source_url":"https://pubmed.ncbi.nlm.nih.gov/34198582/","study_design":null,"title":"Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression","title_match":false,"year":2021},{"alzhub_score":79,"alzhub_url":"https://alzhub.org/study/fatal-iatrogenic-cerebral-amyloid-related-arteritis-in-a-woman-38086820","doi":"10.1038/s41467-023-43933-5","journal":"Nature communications","n_participants":null,"pmid":"38086820","source_url":"https://pubmed.ncbi.nlm.nih.gov/38086820/","study_design":"randomized controlled trial","title":"Fatal iatrogenic cerebral \u03b2-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer's disease","title_match":true,"year":2023},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/detection-and-management-of-amyloid-related-imaging-abnormalities-in-35542992","doi":"10.14283/jpad.2022.21","journal":"The journal of prevention of Alzheimer's disease","n_participants":null,"pmid":"35542992","source_url":"https://pubmed.ncbi.nlm.nih.gov/35542992/","study_design":null,"title":"Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy","title_match":false,"year":2022},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/current-and-future-therapeutic-strategies-for-alzheimer-s-disease-an-37600514","doi":"10.3389/fnagi.2023.1206572","journal":"Frontiers in aging neuroscience","n_participants":null,"pmid":"37600514","source_url":"https://pubmed.ncbi.nlm.nih.gov/37600514/","study_design":null,"title":"Current and future therapeutic strategies for Alzheimer's disease: an overview of drug development bottlenecks","title_match":false,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/anti-amyloid-immunotherapies-for-alzheimer-s-disease-a-2023-clinical-37490245","doi":"10.1007/s13311-023-01405-0","journal":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","n_participants":null,"pmid":"37490245","source_url":"https://pubmed.ncbi.nlm.nih.gov/37490245/","study_design":"clinical trial","title":"Anti-Amyloid Immunotherapies for Alzheimer's Disease: A 2023 Clinical Update","title_match":false,"year":2023},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/perspectives-on-future-alzheimer-therapies-amyloid-protofibrils-a-new-25031633","doi":"10.1186/alzrt246","journal":"Alzheimer's research & therapy","n_participants":null,"pmid":"25031633","source_url":"https://pubmed.ncbi.nlm.nih.gov/25031633/","study_design":"clinical trial","title":"Perspectives on future Alzheimer therapies: amyloid-\u03b2 protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer's disease","title_match":true,"year":2014},{"alzhub_score":40,"alzhub_url":"https://alzhub.org/study/lecanemab-first-approval-36856953","doi":"10.1007/s40265-023-01851-2","journal":"Drugs","n_participants":null,"pmid":"36856953","source_url":"https://pubmed.ncbi.nlm.nih.gov/36856953/","study_design":null,"title":"Lecanemab: First Approval","title_match":true,"year":2023},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/second-generation-anti-amyloid-monoclonal-antibodies-for-alzheimer-s-39865265","doi":"10.1186/s40035-025-00465-w","journal":"Translational neurodegeneration","n_participants":null,"pmid":"39865265","source_url":"https://pubmed.ncbi.nlm.nih.gov/39865265/","study_design":null,"title":"Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectives","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/risk-factors-in-developing-amyloid-related-imaging-abnormalities-aria-38312931","doi":"10.3389/fnins.2024.1326784","journal":"Frontiers in neuroscience","n_participants":null,"pmid":"38312931","source_url":"https://pubmed.ncbi.nlm.nih.gov/38312931/","study_design":null,"title":"Risk factors in developing amyloid related imaging abnormalities (ARIA) and clinical implications","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/antiamyloid-monoclonal-antibody-therapy-for-alzheimer-disease-37495380","doi":"10.1212/wnl.0000000000207757","journal":"Neurology","n_participants":null,"pmid":"37495380","source_url":"https://pubmed.ncbi.nlm.nih.gov/37495380/","study_design":null,"title":"Antiamyloid Monoclonal Antibody Therapy for Alzheimer Disease: Emerging Issues in Neurology","title_match":false,"year":2023},{"alzhub_score":66,"alzhub_url":"https://alzhub.org/study/safety-and-tolerability-of-ban2401-a-clinical-study-in-alzheimer-s-27048170","doi":"10.1186/s13195-016-0181-2","journal":"Alzheimer's research & therapy","n_participants":null,"pmid":"27048170","source_url":"https://pubmed.ncbi.nlm.nih.gov/27048170/","study_design":null,"title":"Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective A\u03b2 antibody","title_match":true,"year":2016},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/aria-in-patients-treated-with-lecanemab-ban2401-in-a-phase-2-study-in-36949897","doi":"10.1002/trc2.12377","journal":"Alzheimer's & dementia (New York, N. Y.)","n_participants":null,"pmid":"36949897","source_url":"https://pubmed.ncbi.nlm.nih.gov/36949897/","study_design":"clinical trial","title":"ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease","title_match":true,"year":2023},{"alzhub_score":79,"alzhub_url":"https://alzhub.org/study/efficacy-and-safety-of-anti-amyloid-monoclonal-antibodies-in-current-37423541","doi":"10.1016/j.arr.2023.102012","journal":"Ageing research reviews","n_participants":14980,"pmid":"37423541","source_url":"https://pubmed.ncbi.nlm.nih.gov/37423541/","study_design":"meta-analysis","title":"Efficacy and safety of anti-amyloid-\u03b2 monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis","title_match":false,"year":2023},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/amyloid-beta-antibody-binding-to-cerebral-amyloid-angiopathy-fibrils-38740836","doi":"10.1038/s41598-024-61691-2","journal":"Scientific reports","n_participants":null,"pmid":"38740836","source_url":"https://pubmed.ncbi.nlm.nih.gov/38740836/","study_design":null,"title":"Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities","title_match":false,"year":2024},{"alzhub_score":52,"alzhub_url":"https://alzhub.org/study/initial-experience-with-lecanemab-and-lessons-learned-in-71-patients-39559868","doi":"10.14283/jpad.2024.159","journal":"The journal of prevention of Alzheimer's disease","n_participants":71,"pmid":"39559868","source_url":"https://pubmed.ncbi.nlm.nih.gov/39559868/","study_design":null,"title":"Initial Experience with Lecanemab and Lessons Learned in 71 Patients in a Regional Medical Center","title_match":true,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/alzheimer-disease-anti-amyloid-immunotherapies-imaging-39179297","doi":"10.3174/ajnr.a8469","journal":"AJNR. American journal of neuroradiology","n_participants":null,"pmid":"39179297","source_url":"https://pubmed.ncbi.nlm.nih.gov/39179297/","study_design":null,"title":"Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities","title_match":false,"year":2025},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/critical-assessment-of-anti-amyloid-monoclonal-antibodies-effects-in-39468148","doi":"10.1038/s41598-024-75204-8","journal":"Scientific reports","n_participants":null,"pmid":"39468148","source_url":"https://pubmed.ncbi.nlm.nih.gov/39468148/","study_design":"systematic review","title":"Critical assessment of anti-amyloid-\u03b2 monoclonal antibodies effects in Alzheimer's disease: a systematic review and meta-analysis highlighting target engagement and clinical meaningfulness","title_match":false,"year":2024},{"alzhub_score":76,"alzhub_url":"https://alzhub.org/study/safety-and-efficacy-of-lecanemab-for-alzheimer-s-disease-a-systematic-37213538","doi":"10.3389/fnagi.2023.1169499","journal":"Frontiers in aging neuroscience","n_participants":null,"pmid":"37213538","source_url":"https://pubmed.ncbi.nlm.nih.gov/37213538/","study_design":"systematic review","title":"Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials","title_match":true,"year":2023},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/lecanemab-for-early-alzheimer-s-disease-appropriate-use-40011173","doi":"10.1016/j.tjpad.2025.100094","journal":"The journal of prevention of Alzheimer's disease","n_participants":null,"pmid":"40011173","source_url":"https://pubmed.ncbi.nlm.nih.gov/40011173/","study_design":null,"title":"Lecanemab for early Alzheimer's disease: Appropriate use recommendations from the French federation of memory clinics","title_match":true,"year":2025},{"alzhub_score":71,"alzhub_url":"https://alzhub.org/study/implications-of-the-approval-of-lecanemab-for-alzheimer-disease-37295957","doi":"10.1212/wnl.0000000000207438","journal":"Neurology","n_participants":null,"pmid":"37295957","source_url":"https://pubmed.ncbi.nlm.nih.gov/37295957/","study_design":"clinical trial","title":"Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?","title_match":true,"year":2023},{"alzhub_score":84,"alzhub_url":"https://alzhub.org/study/comparative-efficacy-and-safety-of-monoclonal-antibodies-for-38429615","doi":"10.1007/s40263-024-01067-2","journal":"CNS drugs","n_participants":21087,"pmid":"38429615","source_url":"https://pubmed.ncbi.nlm.nih.gov/38429615/","study_design":"meta-analysis","title":"Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis","title_match":false,"year":2024},{"alzhub_score":59,"alzhub_url":"https://alzhub.org/study/post-marketing-safety-concerns-with-lecanemab-a-pharmacovigilance-39780222","doi":"10.1186/s13195-024-01669-4","journal":"Alzheimer's research & therapy","n_participants":193,"pmid":"39780222","source_url":"https://pubmed.ncbi.nlm.nih.gov/39780222/","study_design":null,"title":"Post-marketing safety concerns with lecanemab: a pharmacovigilance study based on the FDA Adverse Event Reporting System database","title_match":true,"year":2025},{"alzhub_score":69,"alzhub_url":"https://alzhub.org/study/monoclonal-therapy-with-lecanemab-in-the-treatment-of-mild-alzheimer-39638097","doi":"10.1016/j.arr.2024.102620","journal":"Ageing research reviews","n_participants":null,"pmid":"39638097","source_url":"https://pubmed.ncbi.nlm.nih.gov/39638097/","study_design":"systematic review","title":"Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysis","title_match":true,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibodies-for-alzheimer-s-disease-evidence-41003140","doi":"10.3390/jpm15090437","journal":"Journal of personalized medicine","n_participants":null,"pmid":"41003140","source_url":"https://pubmed.ncbi.nlm.nih.gov/41003140/","study_design":null,"title":"Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease: Evidence, ARIA Risk, and Precision Patient Selection","title_match":false,"year":2025},{"alzhub_score":71,"alzhub_url":"https://alzhub.org/study/lecanemab-in-clinical-practice-real-world-outcomes-in-early-alzheimer-40437535","doi":"10.1186/s13195-025-01763-1","journal":"Alzheimer's research & therapy","n_participants":31,"pmid":"40437535","source_url":"https://pubmed.ncbi.nlm.nih.gov/40437535/","study_design":"longitudinal study","title":"Lecanemab in clinical practice: real-world outcomes in early Alzheimer's disease","title_match":true,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-in-the-era-of-anti-amyloid-beta-39109501","doi":"10.3348/kjr.2024.0105","journal":"Korean journal of radiology","n_participants":null,"pmid":"39109501","source_url":"https://pubmed.ncbi.nlm.nih.gov/39109501/","study_design":null,"title":"Amyloid-Related Imaging Abnormalities in the Era of Anti-Amyloid Beta Monoclonal Antibodies for Alzheimer's Disease: Recent Updates on Clinical and Imaging Features and MRI Monitoring","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/a-combined-physiologically-based-pharmacokinetic-and-quantitative-36632701","doi":"10.1002/psp4.12912","journal":"CPT: pharmacometrics & systems pharmacology","n_participants":null,"pmid":"36632701","source_url":"https://pubmed.ncbi.nlm.nih.gov/36632701/","study_design":null,"title":"A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease","title_match":false,"year":2023},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/re-evaluation-of-the-efficacy-and-safety-of-anti-a-monoclonal-40308765","doi":"10.3389/fphar.2025.1599048","journal":"Frontiers in pharmacology","n_participants":null,"pmid":"40308765","source_url":"https://pubmed.ncbi.nlm.nih.gov/40308765/","study_design":"meta-analysis","title":"Re-evaluation of the efficacy and safety of anti-A\u03b2 monoclonal antibodies (lecanemab/donanemab) in the treatment of early Alzheimer's disease","title_match":true,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/safety-and-effectiveness-of-the-anti-amyloid-monoclonal-antibody-mab-40051090","doi":"10.1002/bcp.70021","journal":"British journal of clinical pharmacology","n_participants":null,"pmid":"40051090","source_url":"https://pubmed.ncbi.nlm.nih.gov/40051090/","study_design":"narrative review","title":"Safety and effectiveness of the anti-amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective","title_match":true,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/lecanemab-appropriate-use-recommendations-by-korean-dementia-39512702","doi":"10.12779/dnd.2024.23.4.165","journal":"Dementia and neurocognitive disorders","n_participants":null,"pmid":"39512702","source_url":"https://pubmed.ncbi.nlm.nih.gov/39512702/","study_design":null,"title":"Lecanemab: Appropriate Use Recommendations by Korean Dementia Association","title_match":true,"year":2024},{"alzhub_score":53,"alzhub_url":"https://alzhub.org/study/ischemic-stroke-associated-with-amyloid-related-imaging-abnormalities-39215494","doi":"10.1002/alz.14223","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"39215494","source_url":"https://pubmed.ncbi.nlm.nih.gov/39215494/","study_design":null,"title":"Ischemic stroke associated with amyloid-related imaging abnormalities in a patient treated with lecanemab","title_match":true,"year":2024},{"alzhub_score":67,"alzhub_url":"https://alzhub.org/study/application-of-meta-analysis-to-evaluate-relationships-among-aria-e-35320578","doi":"10.1007/s43441-022-00390-4","journal":"Therapeutic innovation & regulatory science","n_participants":null,"pmid":"35320578","source_url":"https://pubmed.ncbi.nlm.nih.gov/35320578/","study_design":"meta-analysis","title":"Application of Meta-analysis to Evaluate Relationships Among ARIA-E Rate, Amyloid Reduction Rate, and Clinical Cognitive Response in Amyloid Therapeutic Clinical Trials for Early Alzheimer's Disease","title_match":false,"year":2022},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/sar228810-an-antibody-for-protofibrillar-amyloid-peptide-designed-to-30486882","doi":"10.1186/s13195-018-0447-y","journal":"Alzheimer's research & therapy","n_participants":null,"pmid":"30486882","source_url":"https://pubmed.ncbi.nlm.nih.gov/30486882/","study_design":null,"title":"SAR228810: an antibody for protofibrillar amyloid \u03b2 peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA)","title_match":false,"year":2018},{"alzhub_score":55,"alzhub_url":"https://alzhub.org/study/population-pharmacokinetics-and-exposure-response-analyses-of-safety-39207112","doi":"10.1002/psp4.13224","journal":"CPT: pharmacometrics & systems pharmacology","n_participants":2641,"pmid":"39207112","source_url":"https://pubmed.ncbi.nlm.nih.gov/39207112/","study_design":null,"title":"Population pharmacokinetics and exposure-response analyses of safety (ARIA-E and isolated ARIA-H) of lecanemab in subjects with early Alzheimer's disease","title_match":true,"year":2024},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/monoclonal-antibody-administration-in-an-academic-institution-and-40355750","doi":"10.1007/s00415-025-13142-9","journal":"Journal of neurology","n_participants":165,"pmid":"40355750","source_url":"https://pubmed.ncbi.nlm.nih.gov/40355750/","study_design":null,"title":"Monoclonal antibody administration in an academic institution and private neurological practice: a tale of two clinics","title_match":false,"year":2025},{"alzhub_score":83,"alzhub_url":"https://alzhub.org/study/the-efficacy-and-safety-of-anti-amyloid-monoclonal-antibody-versus-40316479","doi":"10.1016/j.tjpad.2025.100195","journal":"The journal of prevention of Alzheimer's disease","n_participants":8010,"pmid":"40316479","source_url":"https://pubmed.ncbi.nlm.nih.gov/40316479/","study_design":"randomized controlled trial","title":"The efficacy and safety of anti-amyloid monoclonal antibody versus acetylcholinesterase inhibitor with an in-depth analysis across genotypes and disease stages: a systematic review and meta-analysis","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-aria-diagnosis-management-and-38939962","doi":"10.1002/acn3.52042","journal":"Annals of clinical and translational neurology","n_participants":null,"pmid":"38939962","source_url":"https://pubmed.ncbi.nlm.nih.gov/38939962/","study_design":null,"title":"Amyloid-related imaging abnormalities (ARIA): diagnosis, management, and care in the setting of amyloid-modifying therapy","title_match":false,"year":2024},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/the-efficacy-and-safety-of-lecanemab-10-mg-kg-biweekly-compared-to-a-38565747","doi":"10.1007/s10072-024-07477-w","journal":"Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology","n_participants":null,"pmid":"38565747","source_url":"https://pubmed.ncbi.nlm.nih.gov/38565747/","study_design":"systematic review","title":"The efficacy and safety of lecanemab 10 mg/kg biweekly compared to a placebo in patients with Alzheimer's disease: a systematic review and meta-analysis of randomized controlled trials","title_match":true,"year":2024},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/recent-advances-in-antibody-therapy-for-alzheimer-s-disease-focus-on-40650049","doi":"10.3390/ijms26136271","journal":"International journal of molecular sciences","n_participants":null,"pmid":"40650049","source_url":"https://pubmed.ncbi.nlm.nih.gov/40650049/","study_design":null,"title":"Recent Advances in Antibody Therapy for Alzheimer's Disease: Focus on Bispecific Antibodies","title_match":false,"year":2025},{"alzhub_score":76,"alzhub_url":"https://alzhub.org/study/use-of-lecanemab-for-the-treatment-of-alzheimer-s-disease-a-38867460","doi":"10.1002/brb3.3592","journal":"Brain and behavior","n_participants":null,"pmid":"38867460","source_url":"https://pubmed.ncbi.nlm.nih.gov/38867460/","study_design":"meta-analysis","title":"Use of lecanemab for the treatment of Alzheimer's disease: A systematic review","title_match":true,"year":2024},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/lecanemab-a-second-in-class-therapy-for-the-management-of-early-38779110","doi":"10.24926/iip.v15i1.5787","journal":"Innovations in pharmacy","n_participants":null,"pmid":"38779110","source_url":"https://pubmed.ncbi.nlm.nih.gov/38779110/","study_design":null,"title":"Lecanemab: A Second in Class Therapy for the Management of Early Alzheimer's Disease","title_match":true,"year":2024},{"alzhub_score":74,"alzhub_url":"https://alzhub.org/study/lecanemab-treatment-for-alzheimer-s-disease-of-varying-severities-and-41070709","doi":"10.1002/alz.70750","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":68,"pmid":"41070709","source_url":"https://pubmed.ncbi.nlm.nih.gov/41070709/","study_design":"cohort study","title":"Lecanemab treatment for Alzheimer's Disease of varying severities and associated plasma biomarkers monitoring: A multi-center real-world study in China","title_match":true,"year":2025},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/a-systematic-review-of-the-efficacy-and-safety-of-anti-amyloid-40621323","doi":"10.7759/cureus.85377","journal":"Cureus","n_participants":null,"pmid":"40621323","source_url":"https://pubmed.ncbi.nlm.nih.gov/40621323/","study_design":"systematic review","title":"A Systematic Review of the Efficacy and Safety of Anti-amyloid Monoclonal Antibodies in Alzheimer's Disease","title_match":false,"year":2025},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/intracerebral-hemorrhage-following-mild-aria-h-in-an-apoe-2-carrier-39702440","doi":"10.1186/s13195-024-01640-3","journal":"Alzheimer's research & therapy","n_participants":null,"pmid":"39702440","source_url":"https://pubmed.ncbi.nlm.nih.gov/39702440/","study_design":null,"title":"Intracerebral hemorrhage following mild ARIA-H in an APOE \u03b52 carrier receiving lecanemab","title_match":true,"year":2024},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/a-real-world-pharmacovigilance-study-of-adverse-drug-reactions-40290431","doi":"10.3389/fphar.2025.1561020","journal":"Frontiers in pharmacology","n_participants":null,"pmid":"40290431","source_url":"https://pubmed.ncbi.nlm.nih.gov/40290431/","study_design":null,"title":"A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases","title_match":true,"year":2025},{"alzhub_score":53,"alzhub_url":"https://alzhub.org/study/a-real-world-disproportionality-analysis-of-fda-adverse-event-40242445","doi":"10.3389/fphar.2025.1559447","journal":"Frontiers in pharmacology","n_participants":811,"pmid":"40242445","source_url":"https://pubmed.ncbi.nlm.nih.gov/40242445/","study_design":"clinical trial","title":"A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab","title_match":true,"year":2025},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/quantitative-systems-pharmacology-based-exploration-of-relevant-anti-38774587","doi":"10.1002/trc2.12474","journal":"Alzheimer's & dementia (New York, N. Y.)","n_participants":null,"pmid":"38774587","source_url":"https://pubmed.ncbi.nlm.nih.gov/38774587/","study_design":null,"title":"Quantitative systems pharmacology-based exploration of relevant anti-amyloid therapy challenges in clinical practice","title_match":false,"year":2024},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/anti-amyloid-therapies-and-the-transformation-of-alzheimer-s-care-41732200","doi":"10.1016/j.lanepe.2026.101609","journal":"The Lancet regional health. Europe","n_participants":null,"pmid":"41732200","source_url":"https://pubmed.ncbi.nlm.nih.gov/41732200/","study_design":null,"title":"Anti-amyloid therapies and the transformation of Alzheimer's care pathways: early lessons from the frontline","title_match":false,"year":2026},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/two-cases-of-amyloid-related-imaging-abnormalities-aria-following-40624486","doi":"10.1186/s12883-025-04302-5","journal":"BMC neurology","n_participants":null,"pmid":"40624486","source_url":"https://pubmed.ncbi.nlm.nih.gov/40624486/","study_design":null,"title":"Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer's disease and a literature review","title_match":true,"year":2025},{"alzhub_score":59,"alzhub_url":"https://alzhub.org/study/comparison-of-safety-of-lecanemab-and-aducanumab-a-real-world-40520157","doi":"10.3389/fphar.2025.1593989","journal":"Frontiers in pharmacology","n_participants":1409,"pmid":"40520157","source_url":"https://pubmed.ncbi.nlm.nih.gov/40520157/","study_design":null,"title":"Comparison of safety of lecanemab and aducanumab: a real-world disproportionality analysis using the FDA adverse event reporting system","title_match":true,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/more-failure-with-solanezumab-this-time-in-preclinical-alzheimer-s-38414336","doi":"10.1080/14712598.2024.2325551","journal":"Expert opinion on biological therapy","n_participants":null,"pmid":"38414336","source_url":"https://pubmed.ncbi.nlm.nih.gov/38414336/","study_design":"clinical trial","title":"More failure with solanezumab - this time in preclinical Alzheimer's disease","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/alzheimer-s-disease-and-epilepsy-shared-neuropathology-guides-current-37936917","doi":"10.3389/fneur.2023.1241339","journal":"Frontiers in neurology","n_participants":null,"pmid":"37936917","source_url":"https://pubmed.ncbi.nlm.nih.gov/37936917/","study_design":null,"title":"Alzheimer's disease and epilepsy: shared neuropathology guides current and future treatment strategies","title_match":false,"year":2023},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/review-of-anti-amyloid-beta-a-monoclonal-antibodies-for-the-treatment-40940304","doi":"10.1080/17512433.2025.2556122","journal":"Expert review of clinical pharmacology","n_participants":null,"pmid":"40940304","source_url":"https://pubmed.ncbi.nlm.nih.gov/40940304/","study_design":null,"title":"Review of anti-amyloid-beta (A\u03b2) monoclonal antibodies for the treatment of Alzheimer's disease","title_match":false,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/recalibrating-the-risk-benefit-profiles-of-lecanemab-and-donanemab-38701151","doi":"10.3233/jad-240171","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"38701151","source_url":"https://pubmed.ncbi.nlm.nih.gov/38701151/","study_design":null,"title":"Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-\u03b242","title_match":true,"year":2024},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/fda-approved-passive-immunization-treatments-against-a-in-alzheimer-s-41596530","doi":"10.3390/ijms27020883","journal":"International journal of molecular sciences","n_participants":null,"pmid":"41596530","source_url":"https://pubmed.ncbi.nlm.nih.gov/41596530/","study_design":null,"title":"FDA-Approved Passive Immunization Treatments Against A\u03b2 in Alzheimer's Disease: Where Are We Now?","title_match":false,"year":2026},{"alzhub_score":81,"alzhub_url":"https://alzhub.org/study/influence-of-patient-characteristics-on-efficacy-and-safety-of-anti-41352683","doi":"10.1016/j.arr.2025.102981","journal":"Ageing research reviews","n_participants":5633,"pmid":"41352683","source_url":"https://pubmed.ncbi.nlm.nih.gov/41352683/","study_design":"systematic review","title":"Influence of patient characteristics on efficacy and safety of anti-amyloid monoclonal antibodies in Alzheimer's disease: A systematic review and meta-analysis","title_match":false,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/advances-of-therapeutic-strategies-for-alzheimer-s-disease-41107537","doi":"10.1007/s00415-025-13456-8","journal":"Journal of neurology","n_participants":null,"pmid":"41107537","source_url":"https://pubmed.ncbi.nlm.nih.gov/41107537/","study_design":null,"title":"Advances of therapeutic strategies for Alzheimer's disease","title_match":false,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-aria-in-the-context-of-41042497","doi":"10.1007/s40266-025-01253-x","journal":"Drugs & aging","n_participants":null,"pmid":"41042497","source_url":"https://pubmed.ncbi.nlm.nih.gov/41042497/","study_design":null,"title":"Amyloid-related Imaging Abnormalities (ARIA) in the Context of Alzheimer's Disease and Amyloid-targeting Therapies: An Introduction for Advanced Practice Providers","title_match":false,"year":2025},{"alzhub_score":66,"alzhub_url":"https://alzhub.org/study/exploring-the-efficacy-and-safety-of-lecanemab-in-the-management-of-40232258","doi":"10.1177/13872877251331640","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"40232258","source_url":"https://pubmed.ncbi.nlm.nih.gov/40232258/","study_design":"clinical trial","title":"Exploring the efficacy and safety of lecanemab in the management of early Alzheimer's disease: A systematic review of clinical evidence","title_match":true,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/anti-amyloid-monoclonal-antibody-therapies-in-alzheimer-s-disease-a-41077117","doi":"10.1016/j.neuroscience.2025.10.011","journal":"Neuroscience","n_participants":null,"pmid":"41077117","source_url":"https://pubmed.ncbi.nlm.nih.gov/41077117/","study_design":null,"title":"Anti-amyloid monoclonal antibody therapies in Alzheimer's disease - a scoping review","title_match":false,"year":2025},{"alzhub_score":50,"alzhub_url":"https://alzhub.org/study/the-black-book-of-psychotropic-dosing-and-monitoring-38993656","doi":"10.64719/pb.4493","journal":"Psychopharmacology bulletin","n_participants":407,"pmid":"38993656","source_url":"https://pubmed.ncbi.nlm.nih.gov/38993656/","study_design":"clinical trial","title":"The Black Book of Psychotropic Dosing and Monitoring","title_match":false,"year":2024},{"alzhub_score":47,"alzhub_url":"https://alzhub.org/study/balancing-benefit-and-risk-in-early-alzheimer-s-disease-the-european-41852829","doi":"10.1016/j.lanepe.2026.101644","journal":"The Lancet regional health. Europe","n_participants":null,"pmid":"41852829","source_url":"https://pubmed.ncbi.nlm.nih.gov/41852829/","study_design":null,"title":"Balancing benefit and risk in early Alzheimer's disease: the European Medicines Agency (EMA) assessment of lecanemab and donanemab","title_match":true,"year":2026},{"alzhub_score":59,"alzhub_url":"https://alzhub.org/study/real-world-experience-with-baseline-characteristics-and-safety-of-41396015","doi":"10.1177/13872877251406619","journal":"Journal of Alzheimer's disease : JAD","n_participants":190,"pmid":"41396015","source_url":"https://pubmed.ncbi.nlm.nih.gov/41396015/","study_design":null,"title":"Real-world experience with baseline characteristics and safety of lecanemab for Alzheimer's disease in Eastern China","title_match":true,"year":2026},{"alzhub_score":72,"alzhub_url":"https://alzhub.org/study/higher-phosphorylated-tau-levels-predict-cognitive-decline-and-41276859","doi":"10.1186/s13195-025-01912-6","journal":"Alzheimer's research & therapy","n_participants":234,"pmid":"41276859","source_url":"https://pubmed.ncbi.nlm.nih.gov/41276859/","study_design":"longitudinal study","title":"Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice data","title_match":true,"year":2025},{"alzhub_score":56,"alzhub_url":"https://alzhub.org/study/effectiveness-safety-and-biomarker-dynamics-of-lecanemab-in-chinese-41823189","doi":"10.1002/alz.71231","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"41823189","source_url":"https://pubmed.ncbi.nlm.nih.gov/41823189/","study_design":null,"title":"Effectiveness, safety, and biomarker dynamics of lecanemab in Chinese Alzheimer's disease population: a multicenter real-world study","title_match":true,"year":2026},{"alzhub_score":73,"alzhub_url":"https://alzhub.org/study/heterogeneity-in-plasma-p-tau217-response-and-its-association-with-42535277","doi":"10.1002/alz.71705","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":153,"pmid":"42535277","source_url":"https://pubmed.ncbi.nlm.nih.gov/42535277/","study_design":"longitudinal study","title":"Heterogeneity in plasma p-tau217 response and its association with cognitive trajectories under lecanemab treatment","title_match":true,"year":2026},{"alzhub_score":57,"alzhub_url":"https://alzhub.org/study/racial-and-ethnic-differences-in-plasma-p-tau217-ratio-biomarker-40861822","doi":"10.1002/dad2.70164","journal":"Alzheimer's & dementia (Amsterdam, Netherlands)","n_participants":6437,"pmid":"40861822","source_url":"https://pubmed.ncbi.nlm.nih.gov/40861822/","study_design":null,"title":"Racial and ethnic differences in plasma p-tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemab","title_match":true,"year":2025},{"alzhub_score":66,"alzhub_url":"https://alzhub.org/study/real-world-implementation-of-lecanemab-and-donanemab-in-an-italian-41857623","doi":"10.1186/s13195-026-02015-6","journal":"Alzheimer's research & therapy","n_participants":null,"pmid":"41857623","source_url":"https://pubmed.ncbi.nlm.nih.gov/41857623/","study_design":"cohort study","title":"Real-world implementation of lecanemab and donanemab in an Italian memory center: a 1-year experience","title_match":true,"year":2026},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/alzheimer-s-disease-treatment-challenges-for-the-future-40739944","doi":"10.1111/jnc.70176","journal":"Journal of neurochemistry","n_participants":null,"pmid":"40739944","source_url":"https://pubmed.ncbi.nlm.nih.gov/40739944/","study_design":null,"title":"Alzheimer's Disease: Treatment Challenges for the Future","title_match":false,"year":2025},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/passive-anti-amyloid-immunotherapy-in-alzheimer-s-disease-39549715","doi":"10.1016/s0140-6736(24)01883-x","journal":"Lancet (London, England)","n_participants":null,"pmid":"39549715","source_url":"https://pubmed.ncbi.nlm.nih.gov/39549715/","study_design":null,"title":"Passive anti-amyloid \u03b2 immunotherapy in Alzheimer's disease-opportunities and challenges","title_match":false,"year":2024},{"alzhub_score":61,"alzhub_url":"https://alzhub.org/study/eligibility-for-lecanemab-and-donanemab-in-korea-under-appropriate-41225766","doi":"10.1002/alz.70875","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":2726,"pmid":"41225766","source_url":"https://pubmed.ncbi.nlm.nih.gov/41225766/","study_design":null,"title":"Eligibility for lecanemab and donanemab in Korea under Appropriate Use Recommendations","title_match":true,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/treatment-of-alzheimer-disease-39620846","doi":"10.1212/con.0000000000001503","journal":"Continuum (Minneapolis, Minn.)","n_participants":null,"pmid":"39620846","source_url":"https://pubmed.ncbi.nlm.nih.gov/39620846/","study_design":null,"title":"Treatment of Alzheimer Disease","title_match":false,"year":2024},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/lecanemab-appropriate-use-recommendations-for-clinical-practice-in-41390238","doi":"10.1136/jnnp-2025-336597","journal":"Journal of neurology, neurosurgery, and psychiatry","n_participants":null,"pmid":"41390238","source_url":"https://pubmed.ncbi.nlm.nih.gov/41390238/","study_design":null,"title":"Lecanemab appropriate use recommendations for clinical practice in the UK","title_match":true,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/anti-amyloid-therapies-for-alzheimer-s-disease-and-the-amyloid-37833948","doi":"10.3390/ijms241914499","journal":"International journal of molecular sciences","n_participants":null,"pmid":"37833948","source_url":"https://pubmed.ncbi.nlm.nih.gov/37833948/","study_design":null,"title":"Anti-Amyloid Therapies for Alzheimer's Disease and the Amyloid Cascade Hypothesis","title_match":false,"year":2023},{"alzhub_score":82,"alzhub_url":"https://alzhub.org/study/comparative-efficacy-tolerability-and-acceptability-of-donanemab-38253184","doi":"10.1016/j.arr.2024.102203","journal":"Ageing research reviews","n_participants":6547,"pmid":"38253184","source_url":"https://pubmed.ncbi.nlm.nih.gov/38253184/","study_design":"meta-analysis","title":"Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis","title_match":true,"year":2024},{"alzhub_score":80,"alzhub_url":"https://alzhub.org/study/novel-anti-amyloid-beta-a-monoclonal-antibody-lecanemab-for-alzheimer-37902139","doi":"10.1177/03946320231209839","journal":"International journal of immunopathology and pharmacology","n_participants":2729,"pmid":"37902139","source_url":"https://pubmed.ncbi.nlm.nih.gov/37902139/","study_design":"systematic review","title":"Novel anti-amyloid-beta (A\u03b2) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review","title_match":true,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/anti-amyloid-antibodies-and-anti-tau-therapies-for-alzheimer-s-38945936","doi":"10.1248/cpb.c24-00069","journal":"Chemical & pharmaceutical bulletin","n_participants":null,"pmid":"38945936","source_url":"https://pubmed.ncbi.nlm.nih.gov/38945936/","study_design":"clinical trial","title":"Anti-amyloid-\u03b2 Antibodies and Anti-tau Therapies for Alzheimer's Disease: Recent Advances and Perspectives","title_match":false,"year":2024},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/overview-of-alzheimer-s-disease-neuroimaging-initiative-and-future-39711072","doi":"10.1002/alz.14321","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"39711072","source_url":"https://pubmed.ncbi.nlm.nih.gov/39711072/","study_design":null,"title":"Overview of Alzheimer's Disease Neuroimaging Initiative and future clinical trials","title_match":false,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/lecanemab-leqembi-is-not-the-right-drug-for-patients-with-alzheimer-s-37676096","doi":"10.17219/acem/171379","journal":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","n_participants":null,"pmid":"37676096","source_url":"https://pubmed.ncbi.nlm.nih.gov/37676096/","study_design":null,"title":"Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's disease","title_match":true,"year":2023},{"alzhub_score":71,"alzhub_url":"https://alzhub.org/study/a-systematic-review-of-the-efficacy-and-safety-of-anti-amyloid-beta-39432414","doi":"10.1080/14712598.2024.2416947","journal":"Expert opinion on biological therapy","n_participants":null,"pmid":"39432414","source_url":"https://pubmed.ncbi.nlm.nih.gov/39432414/","study_design":null,"title":"A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer's disease","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/lecanemab-for-mild-alzheimer-disease-is-there-a-way-forward-40078953","doi":"10.7573/dic.2024-12-2","journal":"Drugs in context","n_participants":null,"pmid":"40078953","source_url":"https://pubmed.ncbi.nlm.nih.gov/40078953/","study_design":null,"title":"Lecanemab for mild Alzheimer disease - is there a way forward?","title_match":true,"year":2025},{"alzhub_score":71,"alzhub_url":"https://alzhub.org/study/comparisons-of-efficacy-and-safety-of-immunotherapies-for-alzheimer-s-40473116","doi":"10.1016/j.clinme.2025.100336","journal":"Clinical medicine (London, England)","n_participants":null,"pmid":"40473116","source_url":"https://pubmed.ncbi.nlm.nih.gov/40473116/","study_design":"meta-analysis","title":"Comparisons of efficacy and safety of immunotherapies for Alzheimer's disease treatment: A network meta-analysis of randomised controlled trials","title_match":false,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/maximizing-the-benefit-and-managing-the-risk-of-anti-amyloid-40118715","doi":"10.1016/j.neurot.2025.e00570","journal":"Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics","n_participants":null,"pmid":"40118715","source_url":"https://pubmed.ncbi.nlm.nih.gov/40118715/","study_design":null,"title":"Maximizing the benefit and managing the risk of anti-amyloid monoclonal antibody therapy for Alzheimer's disease: Strategies and research directions","title_match":false,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/safety-of-switching-from-lecanemab-to-donanemab-in-20-consecutive-40708311","doi":"10.1177/13872877251361051","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"40708311","source_url":"https://pubmed.ncbi.nlm.nih.gov/40708311/","study_design":null,"title":"Safety of switching from lecanemab to donanemab in 20 consecutive patients with Alzheimer's disease","title_match":true,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/donanemab-another-anti-alzheimer-s-drug-with-risk-and-uncertain-38830549","doi":"10.1016/j.arr.2024.102348","journal":"Ageing research reviews","n_participants":null,"pmid":"38830549","source_url":"https://pubmed.ncbi.nlm.nih.gov/38830549/","study_design":null,"title":"Donanemab, another anti-Alzheimer's drug with risk and uncertain benefit","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/anti-amyloid-antibody-therapies-for-alzheimer-s-disease-38932758","doi":"10.1007/s13139-024-00848-3","journal":"Nuclear medicine and molecular imaging","n_participants":null,"pmid":"38932758","source_url":"https://pubmed.ncbi.nlm.nih.gov/38932758/","study_design":"clinical trial","title":"Anti-amyloid Antibody Therapies for Alzheimer's Disease","title_match":false,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/monoclonal-antibody-treatments-for-alzheimer-s-disease-aducanumab-and-39726673","doi":"10.15190/d.2023.12","journal":"Discoveries (Craiova, Romania)","n_participants":null,"pmid":"39726673","source_url":"https://pubmed.ncbi.nlm.nih.gov/39726673/","study_design":null,"title":"Monoclonal Antibody Treatments for Alzheimer's Disease: Aducanumab and Lecanemab","title_match":true,"year":2023},{"alzhub_score":82,"alzhub_url":"https://alzhub.org/study/comparative-efficacy-tolerability-and-acceptability-of-aducanumab-40386876","doi":"10.1177/02698811251340901","journal":"Journal of psychopharmacology (Oxford, England)","n_participants":6918,"pmid":"40386876","source_url":"https://pubmed.ncbi.nlm.nih.gov/40386876/","study_design":"meta-analysis","title":"Comparative efficacy, tolerability, and acceptability of aducanumab, lecanemab, and donanemab with repetitive transcranial magnetic stimulation on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis","title_match":true,"year":2025},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/donanemab-not-two-without-a-third-37831471","doi":"10.17219/acem/172673","journal":"Advances in clinical and experimental medicine : official organ Wroclaw Medical University","n_participants":null,"pmid":"37831471","source_url":"https://pubmed.ncbi.nlm.nih.gov/37831471/","study_design":null,"title":"Donanemab: Not two without a third","title_match":false,"year":2023},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/identifying-genetic-risk-for-amyloid-related-imaging-abnormalities-38165303","doi":"10.1212/wnl.0000000000208096","journal":"Neurology","n_participants":null,"pmid":"38165303","source_url":"https://pubmed.ncbi.nlm.nih.gov/38165303/","study_design":null,"title":"Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities","title_match":false,"year":2024},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/neuropathology-of-anti-amyloid-immunotherapy-a-case-report-37125554","doi":"10.3233/jad-221305","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"37125554","source_url":"https://pubmed.ncbi.nlm.nih.gov/37125554/","study_design":null,"title":"Neuropathology of Anti-Amyloid-\u03b2 Immunotherapy: A Case Report","title_match":false,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/pharmacological-interventions-in-dementia-41047647","doi":"10.11477/mf.030126030530050943","journal":"No shinkei geka. Neurological surgery","n_participants":null,"pmid":"41047647","source_url":"https://pubmed.ncbi.nlm.nih.gov/41047647/","study_design":null,"title":"[Pharmacological Interventions in Dementia]","title_match":false,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/the-affordability-of-lecanemab-an-amyloid-targeting-therapy-for-37251789","doi":"10.1016/j.lanepe.2023.100657","journal":"The Lancet regional health. Europe","n_participants":null,"pmid":"37251789","source_url":"https://pubmed.ncbi.nlm.nih.gov/37251789/","study_design":null,"title":"The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpoint","title_match":true,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/the-controversy-around-anti-amyloid-antibodies-for-treating-alzheimer-39443750","doi":"10.1038/s44319-024-00294-4","journal":"EMBO reports","n_participants":null,"pmid":"39443750","source_url":"https://pubmed.ncbi.nlm.nih.gov/39443750/","study_design":null,"title":"The controversy around anti-amyloid antibodies for treating Alzheimer's disease : The European Medical Agency's ruling against the latest anti-amyloid drugs highlights the ongoing debate about their safety and efficacy","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/pharmacokinetic-evaluation-of-donanemab-for-the-treatment-of-38758223","doi":"10.1080/17425255.2024.2357637","journal":"Expert opinion on drug metabolism & toxicology","n_participants":null,"pmid":"38758223","source_url":"https://pubmed.ncbi.nlm.nih.gov/38758223/","study_design":null,"title":"Pharmacokinetic evaluation of donanemab for the treatment of Alzheimer's","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/the-tale-of-donanemab-god-is-in-the-details-40899945","doi":"10.1177/13872877251371240","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"40899945","source_url":"https://pubmed.ncbi.nlm.nih.gov/40899945/","study_design":null,"title":"The tale of donanemab: God is in the details","title_match":false,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/lecanemab-more-questions-than-answers-38095822","doi":"10.1007/s40261-023-01331-1","journal":"Clinical drug investigation","n_participants":null,"pmid":"38095822","source_url":"https://pubmed.ncbi.nlm.nih.gov/38095822/","study_design":null,"title":"Lecanemab: More Questions Than Answers!","title_match":true,"year":2024},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/an-anti-amyloid-therapy-works-for-alzheimer-s-disease-why-has-it-36797987","doi":"10.1093/brain/awad049","journal":"Brain : a journal of neurology","n_participants":null,"pmid":"36797987","source_url":"https://pubmed.ncbi.nlm.nih.gov/36797987/","study_design":null,"title":"An anti-amyloid therapy works for Alzheimer's disease: why has it taken so long and what is next?","title_match":false,"year":2023},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/comparing-clinical-effect-sizes-of-souvenaidtm-lecanemab-and-41428477","doi":"10.1177/13872877251406221","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"41428477","source_url":"https://pubmed.ncbi.nlm.nih.gov/41428477/","study_design":null,"title":"Comparing clinical effect sizes of SouvenaidTM, lecanemab, and donanemab in early Alzheimer's disease","title_match":true,"year":2026},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/review-of-donanemab-and-lecanemab-in-mild-dementia-stage-of-alzheimer-41966037","doi":"10.4140/tcp.n.2026.98","journal":"The Senior care pharmacist","n_participants":null,"pmid":"41966037","source_url":"https://pubmed.ncbi.nlm.nih.gov/41966037/","study_design":null,"title":"Review of Donanemab and Lecanemab in Mild Dementia Stage of Alzheimer's Disease: Progress and Challenges","title_match":true,"year":2026},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/the-anti-amyloid-monoclonal-antibody-lecanemab-16-cautionary-notes-37334596","doi":"10.3233/jad-230099","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"37334596","source_url":"https://pubmed.ncbi.nlm.nih.gov/37334596/","study_design":null,"title":"The Anti-Amyloid Monoclonal Antibody Lecanemab: 16 Cautionary Notes","title_match":true,"year":2023},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/therapeutic-news-in-alzheimer-s-disease-soon-a-disease-modifying-35489824","doi":"10.1016/j.neurol.2022.02.456","journal":"Revue neurologique","n_participants":null,"pmid":"35489824","source_url":"https://pubmed.ncbi.nlm.nih.gov/35489824/","study_design":null,"title":"Therapeutic news in Alzheimer's disease: Soon a disease-modifying therapy?","title_match":false,"year":2022},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/alzheimer-s-amyloid-hypothesis-and-antibody-therapy-melting-glaciers-38612701","doi":"10.3390/ijms25073892","journal":"International journal of molecular sciences","n_participants":null,"pmid":"38612701","source_url":"https://pubmed.ncbi.nlm.nih.gov/38612701/","study_design":null,"title":"Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/anti-amyloid-antibody-therapy-for-alzheimer-s-disease-39370836","doi":"10.11477/mf.1416202747","journal":"Brain and nerve = Shinkei kenkyu no shinpo","n_participants":null,"pmid":"39370836","source_url":"https://pubmed.ncbi.nlm.nih.gov/39370836/","study_design":"clinical trial","title":"[Anti-Amyloid Antibody Therapy for Alzheimer's Disease]","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/multi-targeting-phytochemicals-for-alzheimer-s-disease-39815655","doi":"10.1002/ptr.8435","journal":"Phytotherapy research : PTR","n_participants":null,"pmid":"39815655","source_url":"https://pubmed.ncbi.nlm.nih.gov/39815655/","study_design":null,"title":"Multi-Targeting Phytochemicals for Alzheimer's Disease","title_match":false,"year":2025},{"alzhub_score":83,"alzhub_url":"https://alzhub.org/study/lecanemab-for-treatment-of-individuals-with-early-alzheimer-s-disease-41689888","doi":"10.1016/j.tjpad.2026.100507","journal":"The journal of prevention of Alzheimer's disease","n_participants":1795,"pmid":"41689888","source_url":"https://pubmed.ncbi.nlm.nih.gov/41689888/","study_design":"clinical trial","title":"Lecanemab for treatment of individuals with early Alzheimer's Disease (AD) who are apolipoprotein E \u03b54 (ApoE \u03b54) non-carriers or heterozygotes","title_match":true,"year":2026},{"alzhub_score":70,"alzhub_url":"https://alzhub.org/study/real-world-application-of-lecanemab-in-early-stage-alzheimer-s-41250246","doi":"10.1186/s13195-025-01886-5","journal":"Alzheimer's research & therapy","n_participants":14,"pmid":"41250246","source_url":"https://pubmed.ncbi.nlm.nih.gov/41250246/","study_design":"cohort study","title":"Real-world application of lecanemab in early-stage alzheimer's disease: a single-center prospective cohort analysis","title_match":true,"year":2025},{"alzhub_score":70,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormalities-in-japanese-patients-with-41936348","doi":"10.1016/j.tjpad.2026.100562","journal":"The journal of prevention of Alzheimer's disease","n_participants":120,"pmid":"41936348","source_url":"https://pubmed.ncbi.nlm.nih.gov/41936348/","study_design":"longitudinal study","title":"Amyloid-related imaging abnormalities in Japanese patients with Alzheimer's disease treated with Lecanemab: A real-world study","title_match":true,"year":2026},{"alzhub_score":66,"alzhub_url":"https://alzhub.org/study/apoe-guided-lecanemab-dosing-dissociates-aria-e-from-aria-h-the-k-42642841","doi":"10.1002/alz.71765","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"42642841","source_url":"https://pubmed.ncbi.nlm.nih.gov/42642841/","study_design":null,"title":"APOE-guided lecanemab dosing dissociates ARIA-E from ARIA-H: The K-ROAD study","title_match":true,"year":2026},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/antibody-therapy-in-alzheimer-s-disease-42714614","doi":"10.1007/s00391-026-02640-8","journal":"Zeitschrift fur Gerontologie und Geriatrie","n_participants":null,"pmid":"42714614","source_url":"https://pubmed.ncbi.nlm.nih.gov/42714614/","study_design":null,"title":"[Antibody therapy in Alzheimer's disease]","title_match":false,"year":2026},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/from-bench-to-bedside-cutting-edge-and-emerging-therapies-for-40993929","doi":"10.2174/0118715249388723250910140541","journal":"Central nervous system agents in medicinal chemistry","n_participants":null,"pmid":"40993929","source_url":"https://pubmed.ncbi.nlm.nih.gov/40993929/","study_design":null,"title":"From Bench to Bedside: Cutting-Edge and Emerging Therapies for Alzheimer's Disease","title_match":false,"year":2025},{"alzhub_score":48,"alzhub_url":"https://alzhub.org/study/passive-alzheimer-s-immunotherapy-a-promising-or-uncertain-option-37414156","doi":"10.1016/j.arr.2023.101996","journal":"Ageing research reviews","n_participants":null,"pmid":"37414156","source_url":"https://pubmed.ncbi.nlm.nih.gov/37414156/","study_design":null,"title":"Passive Alzheimer's immunotherapy: A promising or uncertain option?","title_match":false,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/amyloid-related-imaging-abnormality-aria-beyond-the-apoe-4-allele-40951730","doi":"10.1002/cdt3.70006","journal":"Chronic diseases and translational medicine","n_participants":null,"pmid":"40951730","source_url":"https://pubmed.ncbi.nlm.nih.gov/40951730/","study_design":null,"title":"Amyloid-Related Imaging Abnormality (ARIA) Beyond the APOE-\u03b54 Allele","title_match":false,"year":2025},{"alzhub_score":63,"alzhub_url":"https://alzhub.org/study/real-world-evidence-for-amyloid-targeted-therapies-lecanemab-and-42661728","doi":"10.1002/dad2.70404","journal":"Alzheimer's & dementia (Amsterdam, Netherlands)","n_participants":89,"pmid":"42661728","source_url":"https://pubmed.ncbi.nlm.nih.gov/42661728/","study_design":null,"title":"Real-world evidence for amyloid-targeted therapies: Lecanemab and donanemab","title_match":true,"year":2026},{"alzhub_score":46,"alzhub_url":"https://alzhub.org/study/messenger-rna-encoded-antibody-approach-for-targeting-extracellular-38585667","doi":"10.1093/braincomms/fcae100","journal":"Brain communications","n_participants":null,"pmid":"38585667","source_url":"https://pubmed.ncbi.nlm.nih.gov/38585667/","study_design":null,"title":"Messenger RNA-encoded antibody approach for targeting extracellular and intracellular tau","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/alzheimer-s-disease-the-past-present-and-future-of-a-globally-38313929","doi":"10.7759/cureus.51705","journal":"Cureus","n_participants":null,"pmid":"38313929","source_url":"https://pubmed.ncbi.nlm.nih.gov/38313929/","study_design":null,"title":"Alzheimer's Disease: The Past, Present, and Future of a Globally Progressive Disease","title_match":false,"year":2024},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/nanobody-therapeutics-in-alzheimer-s-disease-from-molecular-41562774","doi":"10.3390/antib15010001","journal":"Antibodies (Basel, Switzerland)","n_participants":null,"pmid":"41562774","source_url":"https://pubmed.ncbi.nlm.nih.gov/41562774/","study_design":null,"title":"Nanobody Therapeutics in Alzheimer's Disease: From Molecular Mechanisms to Translational Approaches","title_match":false,"year":2025},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/guidelines-for-pharmacotherapy-in-alzheimer-s-disease-a-primer-on-fda-38059250","doi":"10.25259/jnrp_356_2023","journal":"Journal of neurosciences in rural practice","n_participants":null,"pmid":"38059250","source_url":"https://pubmed.ncbi.nlm.nih.gov/38059250/","study_design":null,"title":"Guidelines for pharmacotherapy in Alzheimer's disease - A primer on FDA-approved drugs","title_match":false,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/polypharmacological-potential-of-phosphodiesterase-5-inhibitors-for-38270120","doi":"10.14336/ad.2023.1129","journal":"Aging and disease","n_participants":null,"pmid":"38270120","source_url":"https://pubmed.ncbi.nlm.nih.gov/38270120/","study_design":null,"title":"Polypharmacological Potential of Phosphodiesterase 5 Inhibitors for the Treatment of Neurocognitive Disorders","title_match":false,"year":2024},{"alzhub_score":75,"alzhub_url":"https://alzhub.org/study/lecanemab-clarity-ad-quality-of-life-results-from-a-randomized-double-37874099","doi":"10.14283/jpad.2023.123","journal":"The journal of prevention of Alzheimer's disease","n_participants":1795,"pmid":"37874099","source_url":"https://pubmed.ncbi.nlm.nih.gov/37874099/","study_design":"clinical trial","title":"Lecanemab Clarity AD: Quality-of-Life Results from a Randomized, Double-Blind Phase 3 Trial in Early Alzheimer's Disease","title_match":true,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/mechanism-of-action-and-clinical-trial-results-of-lecanemab-leqembi-38692883","doi":"10.1254/fpj.24005","journal":"Nihon yakurigaku zasshi. Folia pharmacologica Japonica","n_participants":null,"pmid":"38692883","source_url":"https://pubmed.ncbi.nlm.nih.gov/38692883/","study_design":null,"title":"[Mechanism of action and clinical trial results of Lecanemab (Leqembi\u00ae 200 \u200dmg, 500 \u200dmg for Intravenous Infusion), a novel treatment for Alzheimer's disease]","title_match":true,"year":2024},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/elevated-soluble-amyloid-beta-protofibrils-in-down-syndrome-and-34091073","doi":"10.1016/j.mcn.2021.103641","journal":"Molecular and cellular neurosciences","n_participants":null,"pmid":"34091073","source_url":"https://pubmed.ncbi.nlm.nih.gov/34091073/","study_design":"clinical trial","title":"Elevated soluble amyloid beta protofibrils in Down syndrome and Alzheimer's disease","title_match":false,"year":2021},{"alzhub_score":41,"alzhub_url":"https://alzhub.org/study/commentaries-lecanemab-pioneering-the-way-as-the-first-approved-drug-37682322","doi":"10.1007/s00011-023-01788-y","journal":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","n_participants":null,"pmid":"37682322","source_url":"https://pubmed.ncbi.nlm.nih.gov/37682322/","study_design":null,"title":"Commentaries: Lecanemab: pioneering the way as the first approved drug for Alzheimer's disease treatment","title_match":true,"year":2023},{"alzhub_score":54,"alzhub_url":"https://alzhub.org/study/potential-impact-of-unblinding-on-observed-treatment-effects-in-38380503","doi":"10.1002/alz.13690","journal":"Alzheimer's & dementia : the journal of the Alzheimer's Association","n_participants":null,"pmid":"38380503","source_url":"https://pubmed.ncbi.nlm.nih.gov/38380503/","study_design":"clinical trial","title":"Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials","title_match":false,"year":2024},{"alzhub_score":52,"alzhub_url":"https://alzhub.org/study/lifetime-cost-effectiveness-of-lecanemab-for-early-alzheimer-s-disease-41694525","doi":"10.3389/fpubh.2026.1692508","journal":"Frontiers in public health","n_participants":null,"pmid":"41694525","source_url":"https://pubmed.ncbi.nlm.nih.gov/41694525/","study_design":null,"title":"Lifetime cost-effectiveness of lecanemab for early Alzheimer's disease","title_match":true,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/quantitative-systems-pharmacology-analysis-of-amyloid-aggregation-and-a02492d7","doi":"10.21203/rs.3.rs-10570608/v1","journal":"Research Square","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.21203/rs.3.rs-10570608/v1","study_design":"clinical trial","title":"Quantitative Systems Pharmacology Analysis of Amyloid Aggregation and Hippocampal Atrophy Trajectories in Alzheimer\u2019s Disease by APOE4 Genotype and Valiltramiprosate/ALZ-801 Treatment","title_match":false,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/serpin-a3-is-increased-in-cerebral-amyloid-angiopathy-and-aria-4f28fca6","doi":"10.64898/2026.10.19.759840","journal":"bioRxiv","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.64898/2026.10.19.759840","study_design":null,"title":"Serpin A3 is Increased in Cerebral Amyloid Angiopathy and ARIA","title_match":false,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/when-is-amyloid-really-cleared-substantial-discordance-between-fc03ab7d","doi":"10.64898/2026.10.03.26364642","journal":"medRxiv","n_participants":15,"pmid":null,"source_url":"https://doi.org/10.64898/2026.10.03.26364642","study_design":null,"title":"When Is Amyloid Really Cleared? Substantial Discordance Between Centiloid Quantitation and Visual Reads of Amyloid PET after Amyloid-Targeting Therapy","title_match":false,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/brain-resident-myeloid-cells-promote-rapid-leukocyte-adhesion-in-005bc584","doi":"10.64898/2026.09.07.749938","journal":"bioRxiv","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.64898/2026.09.07.749938","study_design":"longitudinal study","title":"Brain-resident myeloid cells promote rapid leukocyte adhesion in leptomeningeal vessels after anti-A\u03b2 immunotherapy","title_match":false,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/amyloid-and-tau-cerebrospinal-fluid-biomarker-normalization-in-a-1d9e787e","doi":"10.21203/rs.3.rs-10778388/v1","journal":"Research Square","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.21203/rs.3.rs-10778388/v1","study_design":null,"title":"Amyloid and Tau Cerebrospinal Fluid Biomarker Normalization in a Patient with Alzheimer\u2019s Disease treated with Lecanemab: A Case Report","title_match":true,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/real-world-characterization-of-amyloid-related-imaging-abnormalities-4202aa20","doi":"10.64898/2026.01.23.26344739","journal":"medRxiv","n_participants":468,"pmid":null,"source_url":"https://doi.org/10.64898/2026.01.23.26344739","study_design":"cohort study","title":"Real-World Characterization of Amyloid-Related Imaging Abnormalities (ARIA) in Lecanemab Treatment at an Academic Health System","title_match":true,"year":2026},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/real-world-experience-with-lecanemab-therapy-for-alzheimers-disease-b62fc105","doi":"10.1101/2025.09.30.25337002","journal":"medRxiv","n_participants":70,"pmid":null,"source_url":"https://doi.org/10.1101/2025.09.30.25337002","study_design":null,"title":"Real-world experience with lecanemab therapy for Alzheimer\u2019s disease in the Intermountain West","title_match":true,"year":2025},{"alzhub_score":16,"alzhub_url":"https://alzhub.org/study/a-transferable-health-economic-evaluation-framework-for-alzheimers-e890aa4f","doi":"10.21203/rs.3.rs-9602832/v1","journal":"Research Square","n_participants":null,"pmid":null,"source_url":"https://doi.org/10.21203/rs.3.rs-9602832/v1","study_design":null,"title":"A Transferable Health Economic Evaluation Framework for Alzheimer\u2019s Disease-Modifying Therapies","title_match":false,"year":2026},{"alzhub_score":45,"alzhub_url":"https://alzhub.org/study/anti-amyloid-therapies-for-alzheimers-disease-progress-pitfalls-and-41096797","doi":"10.3390/ijms26199529","journal":"International Journal of Molecular Sciences","n_participants":null,"pmid":"41096797","source_url":"https://pubmed.ncbi.nlm.nih.gov/41096797/","study_design":null,"title":"Anti-Amyloid Therapies for Alzheimer\u2019s Disease: Progress, Pitfalls, and the Path Ahead","title_match":false,"year":2025},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/assessing-preparedness-for-alzheimer-diseasemodifying-therapies-in-36934371","doi":"10.5694/mja2.51880","journal":"The Medical Journal of Australia","n_participants":null,"pmid":"36934371","source_url":"https://pubmed.ncbi.nlm.nih.gov/36934371/","study_design":"clinical trial","title":"Assessing preparedness for Alzheimer disease\u2010modifying therapies in Australasian health care systems","title_match":false,"year":2023},{"alzhub_score":43,"alzhub_url":"https://alzhub.org/study/population-pharmacokinetic-pharmacodynamic-analyses-of-amyloid-36165093","doi":"10.1002/psp4.12862","journal":"CPT: pharmacometrics & systems pharmacology","n_participants":null,"pmid":"36165093","source_url":"https://pubmed.ncbi.nlm.nih.gov/36165093/","study_design":null,"title":"Population pharmacokinetic-pharmacodynamic analyses of amyloid positron emission tomography and plasma biomarkers for lecanemab in subjects with early Alzheimer's disease","title_match":true,"year":2022},{"alzhub_score":57,"alzhub_url":"https://alzhub.org/study/lecanemab-associated-amyloid-protofibril-in-cerebrospinal-fluid-39761671","doi":"10.1002/ana.27175","journal":"Annals of neurology","n_participants":163,"pmid":"39761671","source_url":"https://pubmed.ncbi.nlm.nih.gov/39761671/","study_design":null,"title":"Lecanemab-Associated Amyloid-\u03b2 Protofibril in Cerebrospinal Fluid Correlates with Biomarkers of Neurodegeneration in Alzheimer's Disease","title_match":true,"year":2025},{"alzhub_score":36,"alzhub_url":"https://alzhub.org/study/the-murine-version-of-ban2401-mab158-selectively-reduces-amyloid-25096615","doi":"10.3233/jad-140741","journal":"Journal of Alzheimer's disease : JAD","n_participants":null,"pmid":"25096615","source_url":"https://pubmed.ncbi.nlm.nih.gov/25096615/","study_design":"clinical trial","title":"The murine version of BAN2401 (mAb158) selectively reduces amyloid-\u03b2 protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice","title_match":true,"year":2015}]}